# 2. Initial Management and Resuscitation of the Trauma Patient

Educational materials and pathways regarding the initial approach to the evaluation, management and resuscitation of the injured patient.

# Adult Traumatic Agonal Arrest and Resuscitation

#### Purpose

<span style="mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;">To outline the procedure for the treatment of the adult traumatic patient with a penetrating or blunt mechanism of injury who has no signs of life.<span style="mso-spacerun: yes;"> </span></span>

**<span style="mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;">In patients without signs of life for &gt;10 minutes in blunt trauma or &gt;15 minutes in penetrating trauma, it is appropriate to terminate resuscitation efforts.<span style="mso-spacerun: yes;"> </span>Trauma surgeon discretion required as reported pre hospital CPR times may be inaccurate.</span>**

#### Definitions

1. <span style="mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;">Blunt trauma –physical impact to the body by some force</span>
2. <span style="mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;">Penetrating trauma - </span><span lang="EN" style="mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin; mso-ansi-language: EN;">occurs when a foreign object pierces the skin and enters the body creating a wound</span>
3. <span style="mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;">Adult trauma patient – any patient age fifteen (15) years or older who has sustained a blunt injury</span>
4. <span style="mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;">Agonal arrest </span><span style="font-family: Symbol; mso-ascii-font-family: Calibri; mso-ascii-theme-font: minor-latin; mso-hansi-font-family: Calibri; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin; mso-char-type: symbol; mso-symbol-font-family: Symbol;"><span style="mso-char-type: symbol; mso-symbol-font-family: Symbol;">-</span></span><span style="mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;"> a severely injured patient in extremis, with no signs of life (absent pulse, absent respirations, absent pupil response, GCS 3)<span style="mso-spacerun: yes;"> </span></span>

#### Background

1. <span style="mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;">Resuscitation of the adult trauma patient who is agonal or arrests as a result of a penetrating or blunt mechanism consist of a rapid assessment and treatment of the various measures of PEA (profound hypovolemia, airway compromise, tension pneumothorax and pericardial tamponade).</span>
2. <span style="mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;">Drowning, lightning strikes, medical causes of cardiac arrest, patients with profound hypothermia or if the patient’s age is 14 years and less are excluded from this guideline.</span>
3. <span style="mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;">The utilization of Advanced Cardiac Life Support (ACLS) and Basic Life Support (BLS) measures, including use of the Lucas device, in the setting of Advance Trauma Life Support (ATLS) resuscitation is of limited, if any, benefit in the setting of blunt traumatic patient arrest.</span>
4. <span style="mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;">Consider previous establishment of the patient’s DNR/DNI status, especially in patients who reside in a long term health care facility.</span>
5. <span style="mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;">Procedures (including airway assessment, chest tubes, etc.) take priority over chest compressions in the **trauma** patient in agonal or arrest states.</span>

#### <span style="mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;">Resuscitation Algorithm </span>

**<u><span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin;">CONSIDER removal of Lucas device/mechanical chest compression device upon patient’s arrival in trauma bay.</span></u>**

1. <span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin;"><span style="text-decoration: underline;">Airway</span>:</span>
    - - <span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin;">Non-intubated patient</span>
            - - Obtain adequate airway (definitive ideal, however, if King, LMA or iGel is adequate, continue until pt stabilizes)
        - <span><span style="font: 7.0pt 'Times New Roman';"> </span></span><span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin;">Confirmation of Airway placement</span>
            - - Visualization of ETT placement through vocal cords, if applicable
                - <span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin;">Colorimetric CO2 detector (may<span style="mso-spacerun: yes;"> </span>not be reliable in arrest)</span>
                - <span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin;">Auscultation of bilateral breath sounds; absence of delivered breath sounds over epigastrium</span>
                - <span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin;">Appropriate O2 Saturation</span>
        - <span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin;">Intubated Patient</span>
            - - <span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin;">Clear communication of assessment to trauma leader</span>
                - <span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin;">Confirmation of airway placement by ER faculty at head of bed</span>
                - <span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin;">Colorimetric CO2 detector (may not be reliable in arrest)</span>
                - <span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin;">Direct laryngoscopy may be considered in setting of any question of placement of ETT.<span style="mso-spacerun: yes;"> </span>Direct laryngoscopy in presence of ETT has a risk of dislodgement of appropriately placed ETT.</span>
                - <span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin;">Auscultation of bilateral breath sounds; absence of delivered breath sounds over epigastrium</span>
                - <span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin;">Appropriate O2 saturation</span>
2. <span style="text-decoration: underline;"><span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin;">Breathing:</span></span>
    - - <span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin;">Bilateral Chest Tube Thoracostomy</span>
        - <span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin;">Resuscitative Thoracotomy (see Western Trauma algorithm below)</span>
3. <span style="text-decoration: underline;"><span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin;">Circulation:</span></span>
    - - <span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin;">Rapid assessment of central (femoral) and peripheral pulses (radial, pedal)</span>
        - <span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin;">Clear communication of assessment to trauma leader</span>
        - <span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin;">Control of life-threatening external hemorrhage (hold pressure, tourniquet, etc)</span>
        - <span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin;">Obtain manual blood pressure (will not be present if no pulse)</span>
        - <span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin;">Confirmation of<span> </span>in-place intravenous (IV) access</span>
        - <span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin;">If no IV access:</span>
            - - <span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin;">Establish IV, Intraosseous (IO) or central access</span>
                - <span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin;">Rapid, early delivery of Whole blood or Packed Red Blood Cells/plasma</span>
                    - - <span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin;">Consider initiation of Massive Blood Transfusion (MBT) protocol</span>
                        - <span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin;">Maintain 1:1:1 ratios</span>
        - <span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin;">Attach cardiac leads/monitor</span>
        - <span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin;">Check Cardiac window on Focused Assessment with Sonography in Trauma (FAST)</span>
            - - <span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin;">Assess for pericardial effusion</span>
                - <span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin;">Assess cardiac kinetic activity</span>
4. <span style="text-decoration: underline;"><span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin;">Disability:</span></span>
    - - <span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin;">Glasgow Coma Scale (GCS) measurement</span>
        - <span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin;">Pupillary response</span>
5. <span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin;">Exposure/Environment</span>
    - - <span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin;">Rapid and complete patient exposure</span>
        - <span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin;">Rapidly cover the exposed patient with warmed blankets (allow above assessment and procedures)</span>
        - <span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin;">Ensure underbody Bair Hugger functional (or provide warmth by another means)</span>

**<span style="mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;">During ABCDEs in a blunt agonal arrest, determine length of time of CPR and quickly assess patient for signs of life (detectable blood pressure, respiratory or motor effort, cardiac electrical activity, or pupillary activity)</span>**

1. <span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin;">If CPR&lt;10 min in blunt trauma or &lt;15 minutes in penetrating trauma, <span style="mso-spacerun: yes;"> </span>AND pt has signs of life, proceed with Resuscitative Thoracotomy (see Western Trauma Association algorithm below).</span>
2. <span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin;">If CPR&gt;10 min in blunt trauma or &lt;15 minutes in penetrating trauma, <span style="mso-spacerun: yes;"> </span><span style="mso-spacerun: yes;"> </span>AND NO signs of life, pt should be pronounced dead.</span>

<span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin;">FIGURE 1. Western Trauma Resuscitative Thoracotomy algorithm </span>

[![image.png](https://paths.trauma.ai/uploads/images/gallery/2024-02/scaled-1680-/8g3image.png)](https://paths.trauma.ai/uploads/images/gallery/2024-02/8g3image.png)

<span style="mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;">[https://www.westerntrauma.org/wp-content/uploads/2020/08/Resuscitative-Thoracotomy\_FINAL.svg](https://www.westerntrauma.org/wp-content/uploads/2020/08/Resuscitative-Thoracotomy_FINAL.svg)</span>

#### <span style="mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;">References</span>

1. <span style="mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;">Trauma patients receiving CPR:<span style="mso-spacerun: yes;"> </span>Predictors of Survival.<span style="mso-spacerun: yes;"> </span>*J Trauma*<span style="mso-spacerun: yes;"> </span>2005 58:951-958.<span style="mso-spacerun: yes;"> </span>Pickens JJ, Copass MK, Bulger EM.</span>
2. <span style="mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;">Blunt Trauma Patients with Prehospital Pulseless Electrical Activity (PEA): Poor Ending Assured. *J Trauma* 2002 53:876-881.<span style="mso-spacerun: yes;"> </span>Martin SK, Shatney CH, Sherck JP, Ho C, Homan SJ, Neff J.</span>
3. <span style="mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;">Confusion Surrounding the Treatment of Traumatic Cardiac Arrest. *Journal of the American College of Surgeons.* Fulton<span style="mso-spacerun: yes;"> </span>RL, Voigt WJ, Hilakos AS.</span>
4. <span style="mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;">Role of External Cardiac Compression in Truncal Trauma. *J Trauma* 1982 Vol. 22 No.11.<span style="mso-spacerun: yes;"> </span>Mattox KL, Feliciano DV.</span>
5. <span style="mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;">Hemodynamic Effects of External Cardiac Massage in Trauma Shock. *J Trauma* 1989 Vol. 29 No. 10.<span style="mso-spacerun: yes;"> </span>Luna GK, Pavilin EG, Kirkman T, Copass MK, Rice CL.</span>
6. <span style="mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;">Guidelines for Withholding or Termination of Resuscitation In Prehospital Traumatic Cardiopulmonary Arrest: A Joint Position Paper From the National Association of EMS Physicians Standards and Clinical Practice Committee and the American College of Surgeons Committee on Trauma. Prehospital Emergency Care January / March 2003 Vol 7 / No. 1 141-146</span>
7. <span style="mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;">Withholding of Resuscitation for Adult Traumatic Cardiopulmonary Arrest: National Association of EMS Physicians and American College of Surgeons Committee on Trauma. Prehospital Emergency Care 2013 17:291</span>

#### <span style="mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;">Authors</span>

<span style="mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;">Charity Evans, MD<span style="font-size: 11.0pt; line-height: 107%; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;"> </span><span style="font-size: 11.0pt; line-height: 107%; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;">| Division of Acute Care Surgery, Faculty | Principle Author </span></span>

#### Last Updated

February, 2024

# Drowning

**Quick Guide:**

Patients should be activated per their physiology and suspected injuries, which will most often be a full trauma given that the majority of suspected injuries include airway issues, level of consciousness/brain injury, and/or spinal cord injuries.

Trauma should be the admitting service to the appropriate level of care. If ICU admission is warranted, the appropriate critical care team should also be consulted (i.e Critical Care Surgery (CCS) for patients &gt;12 yrs of age and Pediatric Critical Care Medicine (PCCM) for patients ≤12 yrs of age).

\*\*Patients who have an event where they are submerged in water but return to baseline at the scene without concern for traumatic injuries do **not** meet these criteria and do **not** need a trauma activation for the submersion event. They may be safely evaluated in the ER and observed by medical admitting services (most often pediatrics).

**Terms**

Drowning is the process of experiencing respiratory impairment from submersion or immersion in liquid.

There are no medically accepted conditions known as “near-drowning,” “dry drowning,” “secondary drowning” or delayed drowning wherein a person was submerged in the water at some point, had no immediate breathing difficulty and later developed delayed onset of respiratory symptoms after a period of being asymptomatic \[3\].

**Epidemiology**

Drowning is the leading cause of death for children ages 1-4, and the second leading cause of unintentional injury-related death for children 5-14 (second only to MVCs) \[1\]. There is another peak among children and young adults aged 15-30, most often due to recreational swimming in natural bodies of water \[2\]. Other risk factors include alcohol consumption, hypothermia, traumatic injury leading to unconsciousness, neurodevelopmental conditions, and seizure disorders.

**Pathophysiology of Injuries**

*Airway:*

Panic results in disruption of normal breathing patterns, subsequent aspiration of fluid leads to laryngospasm and hypoxemia.

*Pulmonary:*

There is no difference between salt and fresh water- both result in hypoxemia and surfactant destruction, predisposing patients to noncardiogenic pulmonary edema and acute respiratory distress syndrome (ARDS).

*Cardiac:*

Arrhythmias may occur secondary to hypoxemia and hypothermia.

*Neurologic:*

Cerebral edema and elevated intracranial pressure develop as consequences of cerebral hypoxia, which is the major contributor to morbidity and mortality.

*Later findings:*

Hypoxia and hypoperfusion can trigger systemic inflammatory response, causing isolated cardiac, renal, or hepatic dysfunction, sepsis, or multiorgan failure. Rarely, patients with normal initial chest x-rays (similar to pulmonary contusions) may develop fulminant pulmonary edema within 12 hours, potentially reflecting delayed ARDS, neurogenic edema, or airway hyperreactivity.

Death from drowning primarily results from hypoxemia caused by water aspiration, which disrupts alveolar gas exchange, destroys surfactant, and produces noncardiogenic pulmonary edema. If rescue does not occur, hypoxia rapidly leads to loss of consciousness, apnea, and hypoxic cardiac arrest, usually presenting with bradycardia or pulseless electrical activity. Later deaths mainly arise from neurologic injury due to prolonged cerebral hypoxia \[5\].

**History &amp; Physical Examination**

-focus the history on duration of submersion, length of extraction/rescue time, whether pulses were lost and/or if CPR was required. The likelihood of diving related injuries associated with the entry into the water are also important.

-additional questions regarding nonaccidental trauma can be added depending on the individual patient’s circumstances.

-obtain labs for toxicology, ethanol, metabolic derangements (most commonly lactic acidosis)

-Physical examination for signs of traumatic injuries as per standard ATLS protocol

**Early Management/Stabilization**

-Patients should be activated per their physiology and suspected injuries, which will most often be a full trauma

-Evaluate ABCs as always (primary and secondary survey per ATLS protocol)

-Immobilization of the spine is recommended for patients who sustained a dive or present with an unknown history

\- Noninvasive positive pressure ventilation or endotracheal intubation may be required to maintain oxygen saturation

-Hypothermia should be addressed by passive rewarming and removal of cold wet clothes

**-**Noncardiogenic pulmonary edema and ARDS may develop over the next 12-24 hours \[6\]

-Glucocorticoids, diuretics, and empiric antibiotics are **not** recommended for routine use. Antibiotic therapy should be initiated only if clinical evidence of infection emerges \[7\]

**Imaging**

\- Chest x-ray

\- Non-contrast CT Head

\- CT C-spine

\- CTA neck and Head

\- Can consider additional CTs (i.e. Trauma “pan scan”) if patient is unconscious, physical exams warrants, or history is concerning for additional injuries or if history is uncertain

**Disposition**

Trauma should be the admitting service to the appropriate level of care:

-Admit critically ill patients to the ICU with either CCS or PCCM consultation

-Admit patients without ICU needs to the Trauma service

-Patients with mild or no symptoms may be observed in the ER for 4-8 hours.

-ECMO may be considered as salvage therapy for refractory hypoxemia or severe hypothermia. These patients would be admitted to the CVICU under CCA for ECMO therapy, with transfer back to trauma floor or ICU as appropriate when weaned from ECMO.

**Author and last update**

Abby Josef, MD, February 2026

**References**

1. Centers for Disease Control and Prevention, National Center for Injury Prevention and Control. Web-based Injury Statistics Query and Reporting System (WISQARS). Accessed 19 January 2026.
2. Gianfrancesco, H; Sternard, BT. Drowning: Clinical Management. https://www.ncbi.nlm.nih.gov/books/NBK430833/ . Accessed 9 February 2026.
3. Spack L, Gedeit R, Splaingard M, Havens PL. Failure of aggressive therapy to alter outcomes in pediatric near-drowning. Pediatric Emergency Care 1997;13(2):98–102.
4. Suominen PK, Vähätalo R. Neurologic long term outcome after drowning in children. Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine 2012;20(55):1–7.
5. Suominen PK, Sutinen N, Valle S, Olkkola KT, Lönnqvist T. Neurocognitive long term follow-up study on drowned children. Resuscitation 2014;85(8):1059–106.
6. <span style="mso-bidi-font-family: Aptos; mso-bidi-theme-font: minor-latin;"><span style="mso-list: Ignore;"><span style="font: 7.0pt 'Times New Roman';"> </span></span>Szpilman D, Morgan PJ. Management for the Drowning Patient</span>
7. Berger S, Siekmeyer M, Petzold-Quinque S, Kiess W, Merkenschlager A. Drowning and Nonfatal Drowning in Children and Adolescents: A Subsequent Retrospective Data Analysis.

# e-FAST for Trauma

#### Purpose

To standardize the application of e-FAST in the seriously injured patient, the technique employed, and the quality of standards by which they are retrospectively evaluated.

#### Background

e-FAST is a valuable diagnostic tool in the evaluation of traumatically injured patients that is able to detect life threatening inra-abdominal hemorrhage, pericardial effusion and hemo/pneumothoraces. An e-FAST exam is non-invasive, does not expose the patient to radiation, can rapidly be performed concurrently with other resuscitative measures, and is repeatable. e-FAST has a sensitivity between 73-88%, a specificity between 98-100%, and an accuracy of 96-98%.

#### Indications for an e-FAST Exam at UNMC/Nebraska Medicine

1. Hemodynamically unstable patients as defined by a systolic blood pressure &lt;90 mmHg for adults and &lt;70mmHg + (2x age in years) for pediatric patients.
2. At the discretion of the Emergency Medicine or Trauma attending.

#### Patients in whom e-FAST should strongly be considered 

1. Pregnant patients

In these special patient populations, if an e-FAST is performed:

- a repeat abdominal ultrasound should be performed 4 hours after the initial e-FAST or sooner if the patient becomes hypotensive.
- a repeat hemoglobin at the time of repeat ultrasound

#### Six views of a complete e-FAST Exam

1. pericardial or subxiphoid view
2. Right upper quadrant: Lung base and hepatorenal recess
3. Left upper quadrant: Lung base and splenorenal recess
4. Pelvic: suprapubic view of bladder/Pouch of Douglass
5. Right anterior thorax
6. left anterior thorax

[![nejmvcm2107283_f2.jpeg](https://paths.trauma.ai/uploads/images/gallery/2023-06/scaled-1680-/nejmvcm2107283-f2.jpeg)](https://paths.trauma.ai/uploads/images/gallery/2023-06/nejmvcm2107283-f2.jpeg)

#### Ordering and Documentation of e-FAST exams

For all patients undergoing an e-FAST exam for trauma:

1. Place an order in the electronic medical record (EPIC) for an e-FAST exam (POC ED US E-FAST, aka FAST)
2. A procedure note will be documented by the provider performing the exam, including indication and interpretation of images.  
    
    1. - the performance of an e-FAST, the indication for exam and results of the exam should also be documented in the trauma H&amp;P.
3. Images will be saved with the patient's MRN.

#### Internal review of e-FAST exams:

The patients in whom e-FAST exams are indicated will be queried and the percentage of those receiving e-FAST exams reported. The documentation, image views and quality, and interpretation of images will be reviewed. Findings will be compared with CT or operative findings. Data will be presented at the monthly Performance Improvement Patient Safety (PIPS) meeting.

#### References

1. AIUM Practice Parameter for the Performance of the Focused Assessment with Sonography for Trauma (FAST) Examination. American Institute of Ultrasound Medicine in collaboration with the American College of Emergency Physicians. [http://www.aium.org/resources/guidelines/fast.pdf](http://www.aium.org/resources/guidelines/fast.pdf).
2. Branney SW, Moore EE, Cantrill SV, et al. Ultrasound based key clinical pathway reduces the use of hospital resources for the evaluation of blunt abdominal trauma. *J Trauma* 42:1086-1090, 1997.
3. Healey MA, Simons RK, WInchell RJ, et al. A prospective evaluation of abdominal ultrasound in blunt trauma: Is it useful? *J Trauma* 40:875-883, 1996.
4. Glaser K, Tschmelitsch J, Klingler P, et al. Ultrasonography in the management of blunt and thoracic trauma. *Arch Surg* 129:743-747, 1994.
5. Liu M, Lee CH, P'eng FK. Prospective comparison of diagnostic peritoneal lavage, computed tomographic scanning and ultrasonography for the diagnosis of blunt abdominal trauma. *J Trauma.* 35:267-270 1993.
6. Boulanger BR, McLellan BA, Brenneman FD, et al. Emergent abdominal sonography as a screening test in a new diagnostic algorithm for blunt trauma. *J Trauma.* 40;867-874, 1996.
7. Boulanger BR, Brenneman FD, McLellan BA, et al. A prospective study of emergent abdominal sonography after blunt trauma. *J Trauma.* 39;325-330, 1995.
8. Ma OJ, Kefer MP, Mateer JR, et al. Evaluation of hemoperitoneum using single vs multiple ultrasonographic examination. *Acad Emerg Med*. 2:581-586, 1995.
9. Rozycki GS, Oshsner MG, Jaffin JH, et al. Prospective evaluation of surgeons' use of ultrasound in the evaluation of trauma patients. *J Trauma*. 34:516-527, 1993.
10. Smith SR, Kern SJ, Fry WR, et al: Institutional learning curve of surgeon-performed trauma ultrasound. *Arch Surg.* 133:530-536, 1998.
11. McKenney MG, Martin L, Lentz K, et al. 1000 consecutive ultrasounds for blunt abdominal trauma. *J Trauma*. 40:607-612, 1996.
12. Kem SJ, Smith RS, Fry WR, et. al. Sonographic examination of abdominal trauma by senior surgical residents. *Am Surg.* 63:669-674, 1997.
13. Rozycki GS, Ochsner MG, Schmidt JA, et al. A prospective study of surgeon-performed ultrasound as the primary adjuvant modality for injured patient assessment. *J Trauma.* 39;492-500, 1995.
14. Ong A, McKenney MG, McKenney KA, et al. Predicting the need for laparotomy in pediatric trauma patietns on the basis of ultrasound score. *J Trauma.* 2003;54:503-508.
15. Soudack M, Epelman M, Maor R, et al. Experience with focused abdominal sonography for trauma (FAST) in 313 pediatric patietns. *J Clin Ultrasound*. 2004;32(2):53-61.
16. McPartland SJ, Jackson C-CA, Gilchrist BF. "Pediatric Blunt Trauma". *Trauma, Critical Care and Surgical Emergencies.* Eds. Rabinovici R, Frankel HL, Kirton O. London:Informa, 2010203-226. Print.

##### UNMC/NM Policy last updated

August, 2019

May, 2025

# Early Femoral Arterial Line Placement for Trauma

#### Purpose

Identify patients who would benefit from early femoral arterial access and describe the process facilitating early femoral arterial access.

#### Background

<span style="font-size: 11.0pt; line-height: 107%; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;">Hemorrhage is the leading cause of preventable death in trauma patients. <span style="mso-spacerun: yes;"> </span>Decision making regarding optimal therapy for the patient experiencing life threatening hemorrhage can be challenging.<span style="mso-spacerun: yes;"> </span>Early femoral arterial access provides additional information by way of continuous blood pressure monitoring. In addition to improved monitoring, common femoral artery (CFA) access is an essential and rate-limiting step in performing hemorrhage control interventions such as resuscitative endovascular balloon occlusion of the aorta (REBOA) or angioembolization. As the hemorrhaging patient progresses further into hemorrhagic shock, CFA access becomes more challenging to obtain.</span>

#### Inclusion Criteria

- Trauma patients with blunt or penetrating mechanism
- <span style="mso-spacerun: yes;"> </span>Concern for life threatening hemorrhage as evidenced by any of the following 
    - - Shock index greater than 1
        - Assessment of Blood Consumption (ABC) score greater than 2
        - Revised Assessment of Bleeding and Transfusion (RABT) score greater than 2
        - Systolic blood pressure less than 90 mmHg
        - Transient or non-responder to initial resuscitation
- Difficulty obtaining non-invasive blood pressure management
- REBOA deployment is considered as an adjunct for hemorrhage control

#### Exclusion Criteria

- Concern for pericardial tamponade
- Concern for supradiaphragmatic hemorrhage
- Patient not a candidate for REBOA

#### Trauma Bay Workflow

- For full trauma activations, ensure that a functioning ultrasound machine is present in the trauma bay, is powered up and otherwise ready to be used
- Ensure either femoral arterial line kit or 5 French micropuncture kit is immediately available
- Ensure that sterile probe cover, Chloraprep and ultrasound gel are immediately available
- Communicate with nursing staff that early CFA access may be pursued giving them time to set up pressure transducer
- Using the criteria above at the discretion of the trauma surgeon or their surrogate, decision to pursue early CFA access is made
- The groin is prepped and draped sterilely
- The linear array ultrasound probe is draped in the usual fashion
- Using real time ultrasound guidance, the CFA is accessed and the catheter placed in the usual fashion. A detailed description of this technique is beyond the scope of this document. Ultrasound guidance should be standard of care, however access by landmarks can be considered on a case by case basis
- Once the catheter has been inserted into the CFA, it is connected to the pressure transducer set up
- The catheter is secured and a sterile dressing is applied
- Depending on the patient’s hemodynamics, their response to resuscitation and their injury pattern, this femoral catheter can remain for hemodynamic monitoring or can be upsized to a 7 French sheath to facilitate placement of REBOA

#### Key Contributors

Kevin Kemp, MD

#### Last Updated

April, 2023

#### References

1. Manning JE, Moore EE, Morrison JJ, Lyon RF, DuBose JJ, Ross JD. Femoral vascular access for endovascular resuscitation. J Trauma Acute Care Surg. 2021 Oct 1;91(4):e104-e113. doi: 10.1097/TA.0000000000003339. PMID: 34238862.
2. Romagnoli A, Teeter W, Pasley J, Hu P, Hoehn M, Stein D, Scalea T, Brenner M. Time to aortic occlusion: It's all about access. J Trauma Acute Care Surg. 2017 Dec;83(6):1161-1164. doi: 10.1097/TA.0000000000001665. PMID: 29190256.
3. Hadley, Jamie B. MD; Coleman, Julia R. MD, MPH; Moore, Ernest E. MD; Lawless, Ryan MD; Burlew, Clay C. MD; Platnick, Barry MD; Pieracci, Fredric M. MD; Hoehn, Melanie R. MD; Coleman, Jamie J. MD; Campion, Eric M. MD; Cohen, Mitchell J. MD; Cralley, Alexis MD; Eitel, Andrew P. MD; Bartley, Matthew MD, MS; Vigneshwar, Navin MD, MPH; Sauaia, Angela MD, PhD; Fox, Charles J. MD. Strategies for successful implementation of resuscitative endovascular balloon occlusion of the aorta in an urban Level I trauma center. Journal of Trauma and Acute Care Surgery 91(2):p 295-301, August 2021. | DOI: 10.1097/TA.0000000000003198
4. Romagnoli, A and Brenner, M. “Principles of REBOA.” Chapter 6, p 81-96. Horer, T et al (eds.). Endovascular Resuscitation and Trauma Management, Hot Topics in Trauma and Acute Care Surgery. Springer Nature 2020.

# Hanging

**Quick Guide:**

Patients should be activated per their physiology and suspected injuries, which will most often be a full trauma given that the majority of suspected injuries include airway issues, level of consciousness/brain injury, and/or spinal cord injuries.

Trauma should be the admitting service to the appropriate level of care. If ICU admission is warranted, the appropriate critical care team should also be consulted (i.e Critical Care Surgery (CCS) for patients &gt;12 yrs of age and Pediatric Critical Care Medicine (PCCM) for patients ≤12 yrs of age).

**Terms/Classification \[1\]**

-“Near-hanging” is a term for patients who have survived an attempted hanging (or at least long enough to reach the hospital).

-“Complete hanging” defines when a patient’s legs are fully suspended off the ground and the patient's bodyweight is fully suspended by the neck.

<span style="mso-spacerun: yes;"> </span>-“Incomplete hanging” defines when some part of the patient’s body is still on the ground and the body's full weight is not suspended off the ground.

<span style="mso-spacerun: yes;"> </span>-“Judicial hanging” classically refers to victims who fell at least the height of their body.

**Epidemiology**

<span style="mso-spacerun: yes;"> </span>-Hanging is the 2nd most common form of successful suicide in the US after firearms. In many areas without access to firearms, hanging is the most common form of successful suicide (England, Australia, New Zealand, also more relevant- in the US jail system)

-Highly lethal (around 70%) but also high survival in those who are rescued and reach the hospital alive (80-90% survival)

-Risk Factors: male, aged 15-44 years, history of drug or alcohol abuse, history of psychiatric illness

**Pathophysiology of Injuries**

*Spine/Spinal Cord:*

-In a judicial hanging, there will almost always be cervical spine injury. The head hyperextends, leading to fracture of the upper cervical spine ("hangman's fracture” of C2) and transection of the spinal cord.

-Cervical injuries in non-judicial hangings are rare. \[2\] One retrospective case review of near-hangings over a 10-year period found the incidence of cervical spine fracture to be as low as 5%. \[3\]

*Vascular*:

The major pathologic mechanism of death in hanging/strangulation is neck vessel occlusion, not airway obstruction. \[1,4\] Death ultimately results from cerebral hypoxia and global ischemia. The most implicated cause of death is venous obstruction. Obstruction of venous outflow from the brain leads to stagnant hypoxia and loss of consciousness in as little as 15 seconds. The risk of damage to the major arterial blood flow to the brain (such as carotid artery dissection) is rare, but should evaluated in patients. \[4\]

*Cardiac*:

Carotid body reflex-mediated cardiac dysrhythmias are reported and may account for a minor mechanism of death.

*Pulmonary*:

-Airway compromise plays less of a role in the immediate death of complete hanging/strangulation. However, it is a major cause of delayed mortality in near-hanging victims. \[1,4\] Airway edema can occur from mechanical trauma to the airway, which can make intubation difficult. Tracheal stenosis can develop later in the hospital course. The hyoid bone can fracture, and injuries to the cricoid or thyroid cartilage can also occur. \[5\]

-Significant pulmonary edema occurs through two mechanisms:

1\) Neurogenic: centrally mediated, massive sympathetic discharge; often in association with serious brain injury.

2\) Post-obstructive: strangulation causes marked negative intrapleural pressure, generated by forceful inspiratory effort against extra-thoracic obstruction; when the obstruction is removed, there is a rapid onset pulmonary edema leading to ARDS.

-Aspiration pneumonitis/pneumonia can cause later sequela of near-hanging injury.

**Physical Examination**

-"Ligature marks" or abrasions, lacerations, contusions, bruising, edema of the neck

-Tardieu spots (petechiae/ecchymoses) of skin or eyes

-Severe pain on gentle palpation of the larynx (laryngeal fracture)

-Respiratory signs: cough, stridor, dysphonia/muffled voice, aphonia

-Varying levels of respiratory distress

-Hypoxemia

-Mental status changes

**Early Management/Stabilization**

-Patients should be activated per their physiology and suspected injuries, which will most often be a full trauma

-Evaluate ABCs as always (primary and secondary survey per ATLS protocol)

-Routine immobilization of the cervical spine is recommended

-Patients who have symptoms such as odynophagia, hoarseness, neurologic changes, or dyspnea may require sudden emergent intubation

-Judicious and cautious fluid resuscitation - avoid large fluid volume resuscitation and consider early pressors, as fluids increase the risk/severity of ARDS and cerebral edema

<span style="mso-spacerun: yes;"> </span>-Monitor for cardiac arrhythmias

-Comatose patients should be assumed to have cerebral edema with elevated ICP and medically managed as such

-Non-intubated patients with pulmonary edema may benefit from noninvasive positive end-expiratory pressure ventilation

-Patients with symptoms of laryngeal or tracheal injury (e.g. dyspnea, dysphonia, aphonia, or odynophagia), should undergo laryngobronchoscopy with ENT \[4,6\]

**Imaging**

\- Chest x-ray

\- Non-contrast CT Head

\- CT C-spine

\- CTA neck and Head

\- Can consider additional CTs (i.e. Trauma “pan scan”) if patient is unconscious, physical exams warrants, or history is concerning for additional injuries or if history is uncertain

**Disposition**

Trauma should be the admitting service to the appropriate level of care:

-Admit critically ill patients to the ICU with either CCS or PCCM consultation

-Admit patients without ICU needs to the Trauma service

-Even if the initial presentation is clinically benign, all near-hanging victims should be observed for 24 hours, given the potential risk of delayed neurologic, airway, and pulmonary complications \[7, 8\]

-Psychiatry consult on all suspected intentional cases

-Emphasize strict return precautions as well as education about possible delayed respiratory and neurologic dysfunction when discharging patients

**Author and last update**

Abby Josef, MD, February 2026

**References**

1\. Walls RM, Hockberger RS, Gausche-Hill M. Rosen's emergency medicine: concepts and clinical practice. Ninth edition. ed. Philadelphia, PA: Elsevier; 2018.

2\. Aufderheide TP, Aprahamian C, Mateer JR, et al. Emergency airway management in hanging victims. Ann Emerg Med. 1994;24(5):879-884.

3\. Salim A, Martin M, Sangthong B, Brown C, Rhee P, Demetriades D. Near-hanging injuries: a 10-year experience. Injury. 2006;37(5):435-439.

4\. Tintinalli JE, Stapczynski JS, Ma OJ, Yealy DM, Meckler GD, Cline DM. Tintinalli's emergency medicine: a comprehensive study guide. 9th. ed. New York: McGraw-Hill Education; 2019.

5\. Tugaleva E, Gorassini DR, Shkrum MJ. Retrospective Analysis of Hanging Deaths in Ontario. J Forensic Sci. 2016;61(6):1498-1507.

6\. Hackett AM, Kitsko DJ. Evaluation and management of pediatric near-hanging injury. Int J Pediatr Otorhinolaryngol. 2013;77(11):1899-1901.

7\. McHugh TP, Stout M. Near-hanging injury. Ann Emerg Med. 1983;12(12):774-776.

8\. Balaji Kannamani, Neeru Sahni, Anjishnujit Bandyopadhyay, Vikas Saini, Laxmi Narayana Yaddanapudi. Insights into pathophysiology, management, and outcomes of near-hanging patients: A narrative review. J Anaesthesiol Clin Pharmacol.<span style="mso-spacerun: yes;"> </span>2024 Oct-Dec;40(4):582-587.

# Management of the Pregnant Trauma Patient

<span style="font-family: 'Arial',sans-serif;"> </span>

**<u><span style="font-family: 'Arial',sans-serif;">Purpose:</span></u><span style="font-family: 'Arial',sans-serif;"> </span>**

<span style="font-family: 'Arial',sans-serif;">Pregnancy alters baseline physiology and anatomy.<span style="mso-spacerun: yes;"> </span>These changes can influence the evaluation of a traumatically injured pregnant patient.<span style="mso-spacerun: yes;"> </span>The signs and symptoms of injury can be confusing.<span style="mso-spacerun: yes;"> </span>The pregnant patient has abnormal baseline laboratory values.<span style="mso-spacerun: yes;"> </span>There are special considerations in the approach and response to resuscitation.<span style="mso-spacerun: yes;"> </span>While there are two patients – mother and fetus, the initial treatment priorities are the same, focusing on the optimal treatment of the mother.<span style="mso-spacerun: yes;"> </span>To provide safe care to the pregnant trauma patient, a collaborative effort between Emergency Medicine, the </span><span style="font-family: 'Arial',sans-serif;">Trauma Service and the Department of Maternal Fetal Medicine should occur.<span style="mso-spacerun: yes;"> </span></span>

<span style="font-family: 'Arial',sans-serif;"> </span>**<u><span style="font-family: 'Arial',sans-serif;">Policy Statement:</span></u>**

<span style="font-family: 'Arial',sans-serif; color: black; mso-themecolor: text1;">This guideline is a supplement to and is to be used in conjunction with the policy Trauma Team Activations (TTA01).<span style="mso-spacerun: yes;"> </span><span style="mso-spacerun: yes;"> </span></span>

<span style="font-family: 'Arial',sans-serif; color: black; mso-themecolor: text1;"> </span><span style="font-family: 'Arial',sans-serif; color: black; mso-themecolor: text1;">Non-trauma activated/minor trauma patients &gt; 20 weeks seen in the Emergency Department (ED) by Emergency Medicine should have an OB consult within 1 hour of presentation to the ED even for minor trauma.</span><span style="font-family: 'Arial',sans-serif;"> </span>

<span style="font-family: 'Arial',sans-serif;">All pregnant trauma patients will be evaluated in an organized fashion whether they be evaluated in the ED, on the floor, or in Labor and Delivery.<span style="mso-spacerun: yes;"> </span>Obstetrics, including Maternal Fetal Medicine, is available to consult on any pregnant patient &lt;20 weeks at any time to discuss medication risks or risk of surgery in pregnancy.<span style="mso-spacerun: yes;"> </span>Additionally, if a pregnant trauma patient at any gestational age cannot be bedded on the trauma floor, contact Labor and Delivery. </span>

<span style="font-family: 'Arial',sans-serif;"> </span>![](https://paths.trauma.ai/uploads/images/gallery/2026-02/embedded-image-6fbjprsh.png)


#### References

1. <span style="font-size: 9.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Arial;"><span style="mso-list: Ignore;">1.<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><span style="font-size: 9.0pt; font-family: 'Arial',sans-serif;">American College of Surgeons Committee on Trauma. (2025). *ATLS, Advanced Trauma Life Support: Student Course Manual*. 11th ed. American College of Surgeons.</span>

##### Author(s)

1. Acute Care Surgery/Trauma Leadership
2. Emergency Medicine Leadership
3. Maternal Fetal Medicine Division Leadership

##### Last Updated

February, 2026

# Massive Transfusion for Trauma Protocol

#### Purpose

<span style="font-size: 12.0pt; line-height: 107%;">Hemorrhage is the leading cause of early death following traumatic injury. Protocol-driven transfusion strategies that approach a 1:1:1 ratio in patients who require massive transfusion improve patient survival, reduce hospital and ICU length of stay, decrease ventilator days, and ultimately reduce patient care costs. </span>

<span style="font-size: 12.0pt; line-height: 107%;">These guidelines are meant to standardize the approach to resuscitation of an injured patient in hemorrhagic shock utilizing massive transfusion. </span>

<span style="font-size: 12.0pt; line-height: 107%;">This guideline is a supplement to and is to be used in conjunction with Nebraska Medicine’s organizational policies “Massive Transfusion/Severe Coagulopathy” (TX-36) and “Guidelines for Management in Patients Receiving Anticoagulation” (MP 11). </span>

#### Background/Definitions

<span style="font-size: 12.0pt; line-height: 107%;">Massive transfusion may be defined as transfusion in response to massive and uncontrolled hemorrhage resulting in any of the following:</span>

- <span style="font-size: 12.0pt; line-height: 107%;">Replacement of half of a patient’s total blood volume in a 4 hour period</span>
- <span style="font-size: 12.0pt; line-height: 107%;">Replacement of a patient’s total blood volume within 24 hours</span>
- <span style="font-size: 12.0pt; line-height: 107%;">Transfusion of &gt;10 units of PRBCs in 24 hours</span>
- <span style="font-size: 12.0pt; line-height: 107%;">Specific pediatric parameters are more challenging to define and include transfusion of &gt;40mL/kg PRBCs in a short period of time. </span>

<span style="font-size: 12.0pt; line-height: 107%;">Hemorrhage is the most common cause of death within the first hour of arrival to a trauma center. Blood product resuscitation, specifically massive transfusions, are often unplanned and require the processing and delivery of large amounts of blood products rapidly for a sustained period of time, significant preplanning and coordination between the blood bank, resuscitating unit (i.e. emergency department, operating room, intensive care unit) and pharmacy is required. The initiation of a massive transfusion protocol (MTP) outlines a standard process for the safe, rapid preparation and delivery of blood products and coagulation factors for the pediatric patient experiencing massive hemorrhage. Additionally, implementation of a standardized guideline may prevent the anticipated complications of massive transfusion including thrombocytopenia, coagulopathies, electrolyte and acid/base disturbances, hypothermia and transfusion reactions as well as utilize valuable blood components in a resourceful manner. </span>

<span style="font-size: 12.0pt; line-height: 107%;">At Nebraska Medicine, the massive transfusion protocol is divided into 3 categories based on the patient’s weight with each pack within that category containing the following blood product components.</span>

<table border="1" cellpadding="0" cellspacing="0" class="MsoTableGrid align-center" id="bkmrk-mtp-type-packed-red-" style="border-collapse: collapse; border: none; mso-border-alt: solid windowtext .5pt; mso-yfti-tbllook: 1184; mso-padding-alt: 0in 5.4pt 0in 5.4pt;"><tbody><tr style="mso-yfti-irow: 0; mso-yfti-firstrow: yes;"><td style="width: 93.5pt; border: solid windowtext 1.0pt; mso-border-alt: solid windowtext .5pt; padding: 0in 5.4pt 0in 5.4pt;" valign="top" width="125"><span style="font-size: 10.0pt;">MTP type</span>

</td><td style="width: 93.5pt; border: solid windowtext 1.0pt; border-left: none; mso-border-left-alt: solid windowtext .5pt; mso-border-alt: solid windowtext .5pt; padding: 0in 5.4pt 0in 5.4pt;" valign="top" width="125"><span style="font-size: 10.0pt;">Packed Red Blood Cells (PRBC)</span>

</td><td style="width: 93.5pt; border: solid windowtext 1.0pt; border-left: none; mso-border-left-alt: solid windowtext .5pt; mso-border-alt: solid windowtext .5pt; padding: 0in 5.4pt 0in 5.4pt;" valign="top" width="125"><span style="font-size: 10.0pt;">Thawed Plasma (FFP)</span>

</td><td style="width: 93.5pt; border: solid windowtext 1.0pt; border-left: none; mso-border-left-alt: solid windowtext .5pt; mso-border-alt: solid windowtext .5pt; padding: 0in 5.4pt 0in 5.4pt;" valign="top" width="125"><span style="font-size: 10.0pt;">Apheresis Platelets</span>

</td><td style="width: 93.5pt; border: solid windowtext 1.0pt; border-left: none; mso-border-left-alt: solid windowtext .5pt; mso-border-alt: solid windowtext .5pt; padding: 0in 5.4pt 0in 5.4pt;" valign="top" width="125"><span style="font-size: 10.0pt;">Pre-pooled cryoprecipitate (cryo)</span>

</td></tr><tr style="mso-yfti-irow: 1;"><td style="width: 93.5pt; border: solid windowtext 1.0pt; border-top: none; mso-border-top-alt: solid windowtext .5pt; mso-border-alt: solid windowtext .5pt; padding: 0in 5.4pt 0in 5.4pt;" valign="top" width="125"><span style="font-size: 10.0pt;">Adult (&gt; 40 kg)</span>

</td><td style="width: 93.5pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; mso-border-top-alt: solid windowtext .5pt; mso-border-left-alt: solid windowtext .5pt; mso-border-alt: solid windowtext .5pt; padding: 0in 5.4pt 0in 5.4pt;" valign="top" width="125"><span style="font-size: 10.0pt;">6 (O pos)</span>

</td><td style="width: 93.5pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; mso-border-top-alt: solid windowtext .5pt; mso-border-left-alt: solid windowtext .5pt; mso-border-alt: solid windowtext .5pt; padding: 0in 5.4pt 0in 5.4pt;" valign="top" width="125"><span style="font-size: 10.0pt;">6 (A)</span>

</td><td style="width: 93.5pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; mso-border-top-alt: solid windowtext .5pt; mso-border-left-alt: solid windowtext .5pt; mso-border-alt: solid windowtext .5pt; padding: 0in 5.4pt 0in 5.4pt;" valign="top" width="125"><span style="font-size: 10.0pt;">1</span>

</td><td style="width: 93.5pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; mso-border-top-alt: solid windowtext .5pt; mso-border-left-alt: solid windowtext .5pt; mso-border-alt: solid windowtext .5pt; padding: 0in 5.4pt 0in 5.4pt;" valign="top" width="125"><span style="font-size: 10.0pt;">On pack #3 and every pack thereafter</span>

</td></tr><tr style="mso-yfti-irow: 2;"><td style="width: 93.5pt; border: solid windowtext 1.0pt; border-top: none; mso-border-top-alt: solid windowtext .5pt; mso-border-alt: solid windowtext .5pt; padding: 0in 5.4pt 0in 5.4pt;" valign="top" width="125"><span style="font-size: 10.0pt;">Pediatric (10-40kg)</span>

</td><td style="width: 93.5pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; mso-border-top-alt: solid windowtext .5pt; mso-border-left-alt: solid windowtext .5pt; mso-border-alt: solid windowtext .5pt; padding: 0in 5.4pt 0in 5.4pt;" valign="top" width="125"><span style="font-size: 10.0pt;">6 (O pos)</span>

</td><td style="width: 93.5pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; mso-border-top-alt: solid windowtext .5pt; mso-border-left-alt: solid windowtext .5pt; mso-border-alt: solid windowtext .5pt; padding: 0in 5.4pt 0in 5.4pt;" valign="top" width="125"><span style="font-size: 10.0pt;">6 (a)</span>

</td><td style="width: 93.5pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; mso-border-top-alt: solid windowtext .5pt; mso-border-left-alt: solid windowtext .5pt; mso-border-alt: solid windowtext .5pt; padding: 0in 5.4pt 0in 5.4pt;" valign="top" width="125"><span style="font-size: 10.0pt;">1</span>

</td><td style="width: 93.5pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; mso-border-top-alt: solid windowtext .5pt; mso-border-left-alt: solid windowtext .5pt; mso-border-alt: solid windowtext .5pt; padding: 0in 5.4pt 0in 5.4pt;" valign="top" width="125"><span style="font-size: 10.0pt;">On pack #3 and every pack thereafter</span>

</td></tr><tr style="mso-yfti-irow: 3; mso-yfti-lastrow: yes;"><td style="width: 93.5pt; border: solid windowtext 1.0pt; border-top: none; mso-border-top-alt: solid windowtext .5pt; mso-border-alt: solid windowtext .5pt; padding: 0in 5.4pt 0in 5.4pt;" valign="top" width="125"><span style="font-size: 10.0pt;">Neonate/Infant (&lt;10 kg)</span>

</td><td style="width: 93.5pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; mso-border-top-alt: solid windowtext .5pt; mso-border-left-alt: solid windowtext .5pt; mso-border-alt: solid windowtext .5pt; padding: 0in 5.4pt 0in 5.4pt;" valign="top" width="125"><span style="font-size: 10.0pt;">1 (O neg, irradiated)</span>

</td><td style="width: 93.5pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; mso-border-top-alt: solid windowtext .5pt; mso-border-left-alt: solid windowtext .5pt; mso-border-alt: solid windowtext .5pt; padding: 0in 5.4pt 0in 5.4pt;" valign="top" width="125"><span style="font-size: 10.0pt;"> </span>

</td><td style="width: 93.5pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; mso-border-top-alt: solid windowtext .5pt; mso-border-left-alt: solid windowtext .5pt; mso-border-alt: solid windowtext .5pt; padding: 0in 5.4pt 0in 5.4pt;" valign="top" width="125"><span style="font-size: 10.0pt;">1 (irradiated)</span>

</td><td style="width: 93.5pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; mso-border-top-alt: solid windowtext .5pt; mso-border-left-alt: solid windowtext .5pt; mso-border-alt: solid windowtext .5pt; padding: 0in 5.4pt 0in 5.4pt;" valign="top" width="125"><span style="font-size: 10.0pt;"> </span>

</td></tr></tbody></table>


#### Guideline Inclusion Criteria

<span style="font-size: 12.0pt; line-height: 107%;">Injured patients with concern for massive or uncontrolled hemorrhage. </span>

#### Guideline Exclusion Criteria

<span style="font-size: 12.0pt; line-height: 107%;">This is a guideline only. Individual circumstances need to be considered, as there may be times when it is appropriate to deviate from this guideline. </span>

#### Diagnostic Evaluation

<span style="font-size: 12.0pt; line-height: 107%;">Injured patients should be assessed per ATLS guidelines paying close attention to circulation. Presence or history of hemodynamic instability, poor perfusion and external blood loss are red flags for hemorrhage. Signs of hemodynamic instability or poor perfusion may include altered mental status, pallor, delayed capillary refill, tachycardia, and hypotension. Hypotension is often a late sign of hypovolemic/hemorrhagic shock. </span>

#### Practice Recommendations for Management

<u><span style="font-size: 12.0pt; line-height: 107%;">Initiation and Activation</span></u>

- <span style="font-size: 12pt;">The decision to activate MTP is a clinical decision made by the trauma or emergency medicine attending physician and should be strongly considered with one or more of the following criteria:</span>
    - - <span style="font-size: 12.0pt; line-height: 107%;">Persistent hemodynamic instability</span>
        - <span style="font-size: 12.0pt; line-height: 107%;">Shock Index &gt;1 (SI = HR/SBP)</span>
        - <span style="font-size: 12.0pt; line-height: 107%;">Active bleeding requiring operation or angioembolization</span>
        - <span style="font-size: 12.0pt; line-height: 107%;">Blood transfusion in the Trauma Bay</span>
        - <span style="font-size: 12.0pt; line-height: 107%;">Adult patients (&gt;40 kg)--Anticipated of transfusion of &gt;10 units PRBC in 24 hrs or &gt;4 units in 1 hr.</span>
        - <span style="font-size: 12.0pt; line-height: 107%;">Pediatric patients (</span><span style="font-size: 12.0pt; line-height: 107%; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;">≤</span><span style="font-size: 12.0pt; line-height: 107%;">40kg) -- Anticipated or actual use of </span><span style="font-size: 12.0pt; line-height: 107%; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;">≥</span><span style="font-size: 12.0pt; line-height: 107%;"> 40 mL/kg PRBCs in 2 hours or replacement of total blood volume (approximately </span><span style="font-size: 12.0pt; line-height: 107%; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;">≥</span><span style="font-size: 12.0pt; line-height: 107%;"> 80 mL/kg) in 24 hrs </span>
        - <span style="font-size: 12.0pt; line-height: 107%;">Assessment of blood consumption (ABC) score is </span>**<span style="font-size: 12.0pt; line-height: 107%; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;">≥</span><span style="font-size: 12.0pt; line-height: 107%;">2</span>**<span style="font-size: 12.0pt; line-height: 107%;"> (adults only):</span>
            - - <span style="font-size: 12.0pt; line-height: 107%;">Penetrating mechanism of injury (1pt)</span>
                - <span style="font-size: 12.0pt; line-height: 107%;">Systolic blood pressure less than or equal to 90 mm Hg (1pt)</span>
                - <span style="font-size: 12.0pt; line-height: 107%;">Heart rate greater than or equal to 120 (1pt)</span>
                - <span style="font-size: 12.0pt; line-height: 107%;">Positive FAST exam (1pt) <span style="mso-spacerun: yes;"> </span></span>
- <span style="font-size: 12.0pt; line-height: 107%;">Initiation of MTP should not be delayed for lab results.</span>
    - - <span style="font-size: 12.0pt; line-height: 107%;">Universally compatible RBC (O Rh-negative) and thawed plasma may be given.</span>
- <span style="font-size: 12.0pt; line-height: 107%;">Emergency release blood should be utilized as indicated until MTP blood products are available.</span>
    - - <span style="font-size: 12.0pt; line-height: 107%;">Whole blood is preferred in the initial resuscitation of hemorrhagic shock in patients age 6 and older. </span>
            - - <span style="font-size: 12.0pt; line-height: 107%;">4 units of whole blood (O positive) are available for trauma resuscitations in the emergency department (ED) and can be found in the ED trauma bay kiosk refrigerator pending inventory availability.</span>
                - <span style="font-size: 16px;">Use of whole blood in pediatric patients age 6-12 years of age should be limited to **1 unit** due to potential risk of hemolysis. </span>
        - <span style="font-size: 12.0pt; line-height: 107%;">Emergency release blood is located in the following locations:</span>
            - - <span style="font-size: 12.0pt; line-height: 107%;">Emergency Department (ED) trauma bay kiosk refrigerators (2 kiosks located in T1 and T4) each containing 2 units O positive whole blood, 2 units O negative PRBC, 6 units O positive PRBCs, and 3 units A plasma</span>
                - <span style="font-size: 12.0pt; line-height: 107%;">Blood bank keeps 4 units O negative PRBC, 12 units O positive PRBC, 12 units A plasma, 8 units platelets, and 25 units pre-pooled cryoglobulin (frozen). <span style="mso-spacerun: yes;"> </span></span>
- <span style="font-size: 12.0pt; line-height: 107%;">To activate the MTP, the attending physician (or designee) will notify the Blood Bank via telephone (402-559-3639) that MTP is being activated and provide the following information:</span>
    - - <span style="font-size: 12.0pt; line-height: 107%;">Caller name and title</span>
        - <span style="font-size: 12.0pt; line-height: 107%;">Caller location</span>
        - <span style="font-size: 12.0pt; line-height: 107%;">Caller contact number</span>
        - <span style="font-size: 12.0pt; line-height: 107%;">Ordering provider’s name</span>
        - <span style="font-size: 12.0pt; line-height: 107%;">Patient’s name (may be the trauma name or real name)</span>
        - <span style="font-size: 12.0pt; line-height: 107%;">Patient’s MRN</span>
        - <span style="font-size: 12.0pt; line-height: 107%;">Category of MTP being activated (adult, pediatric, neonate/infant) </span>
        - <span style="font-size: 12.0pt; line-height: 107%;">Patient’s weight (kg)</span>

<u><span style="font-size: 12.0pt; line-height: 107%;">Blood Product Administration and Transfusion Goals</span></u>

- <span style="font-size: 12.0pt; line-height: 107%;">Minimize crystalloid or colloid resuscitation to prevent dilutional coagulopathy. </span>
- <span style="font-size: 12.0pt; line-height: 107%;">Utilize emergency release blood products until MTP products are available. </span>
- <span style="font-size: 12.0pt; line-height: 107%;">Blood products are released in 1:1 ratios of whole units but will be administered based on the clinical status of the patient and at the discretion of the attending physician. </span>
    - - <span style="font-size: 12.0pt; line-height: 107%;">Maintaining a 1:1:1 transfusion ration of PRBC to FFP to Platelets is recommended. (Platelets are pooled-packs thus one apheresis platelets should be transfused for every 6 units of PRBC/FFP with the exception of neonatal/infant MTP resuscitations where apheresis platelets serves as FFP and platelet components). These rations help to avoid dilutional coagulopathy and thrombocytopenia and have been associated with decreased mortality.</span>

- <span style="font-size: 12.0pt; line-height: 107%; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><span style="mso-list: Ignore;"><span style="font: 7.0pt 'Times New Roman';"> </span></span></span>**<u><span style="font-size: 12.0pt; line-height: 107%;">Pediatric Patients</span></u>**<u><span style="font-size: 12.0pt; line-height: 107%;"> (</span></u><u><span style="font-size: 12.0pt; line-height: 107%; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;">≤</span></u><u><span style="font-size: 12.0pt; line-height: 107%;">40 kg)</span></u><span style="font-size: 12.0pt; line-height: 107%;">, recommended volumes include: </span>
    - - <span style="font-size: 12.0pt; line-height: 107%;">Whole blood -- 20 mL/kg</span>
            - - <span style="font-size: 12.0pt; line-height: 107%;">if using whole blood during pediatric MTP, utilize entire unit of whole blood with repeated boluses of 20mL/kg before moving on to blood components. </span>
        - <span style="font-size: 12.0pt; line-height: 107%;">PRBC – 20 mL/kg</span>
        - <span style="font-size: 12.0pt; line-height: 107%;">FFP – 20 mL/kg</span>
        - <span style="font-size: 12.0pt; line-height: 107%;">Apheresis Platelets – 5 mL/kg</span>
        - <span style="font-size: 12.0pt; line-height: 107%;">Cryoprecipitate – 0.1 unit/kg</span>
            - - <span style="font-size: 12.0pt; line-height: 107%;">Consider cryoprecipitate if serum fibrinogen levels remain less than 150 mg/dL following FFP.</span>

- <span style="font-size: 12.0pt; line-height: 107%;">Massive transfusion products should be administered rapidly and warmed via a rapid infuser with the exception of platelets</span>
    - - <span style="font-size: 12.0pt; line-height: 107%;">For pediatric patients requiring smaller volumes, a “push-pull” system with 60mL syringe, stop-cock, and tubing may be utilized. </span>
- <span style="font-size: 12.0pt; line-height: 107%;">Initial rate of transfusion should restore perfusion but allow permissive hypotension until bleeding has been controlled in the operating room or interventional radiology. </span>
- <span style="font-size: 12.0pt; line-height: 107%;">Blood product resuscitation should be based on clinical evidence of ongoing bleeding in addition to quantitative data, such as ROTEM when available. </span>
- <span style="font-size: 12.0pt; line-height: 107%;">Utilization of the patient’s own blood when safe (i.e. cell saver, autotransfusion from chest tube, etc) also provides readily available warm, matched blood.</span>

<u><span style="font-size: 12.0pt; line-height: 107%;">Therapeutic Adjuncts in MTP</span></u>

<span style="font-size: 12.0pt; line-height: 107%;">Tranexamic Acid (TXA)</span>

- <span style="font-size: 12.0pt; line-height: 107%;">TXA is an antifibrinolytic used to treat coagulopathy. TXA should be initiated early in the coagulopathic cascade – within the first 3 hours of bleeding, in order to be effective. </span>
- <span style="font-size: 12.0pt; line-height: 107%;">TXA should be administered based on the evidence of shutdown of fibrinolysis or hyper-fibrinolysis on ROTEM and/or provider discretion.</span>
- <span style="font-size: 12.0pt; line-height: 107%;">Recommended dosing:</span>
    - - <span style="font-size: 12.0pt; line-height: 107%;">&lt;12 years:</span>
            - - <span style="font-size: 12.0pt; line-height: 107%;">Loading dose of 15 mg/kg (max dose 1000mg) intravenous administered over 10 minutes </span>
                - <span style="font-size: 12.0pt; line-height: 107%;">Maintenance infusion of 2mg/kg/hr intravenous for 8 hours (max dose 1000mg) </span>
        - <span style="font-size: 12.0pt; line-height: 107%; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;">≥</span><span style="font-size: 12.0pt; line-height: 107%;">12 years/Adult Dosing:</span>
            - - <span style="font-size: 12.0pt; line-height: 107%;">Loading dose of 1000 mg intravenous administered over 10 minutes</span>
                - <span style="font-size: 12.0pt; line-height: 107%;">Maintenance infusion of 1000 mg intravenous over 8 hours</span>

<span style="font-size: 12.0pt; line-height: 107%;">Calcium </span>

- <span style="font-size: 12.0pt; line-height: 107%;">The rapid rate of transfusion during MTP often exceeds the liver’s capacity to metabolize citrate, leading to severe hypocalcemia. Calcium is also required by several clotting factors for activation, stabilization of thrombus formation and contractility of myocardial and smooth muscle cells. Hypocalcemia can lead to coagulopathy, myocardial depression and vasodilation—all physiologic changes that complicate the management of hemorrhagic shock. Thus, adequate calcium repletion is an important component of MTP.</span>
- <span style="font-size: 12.0pt; line-height: 107%; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><span style="mso-list: Ignore;"><span style="font: 7.0pt 'Times New Roman';"> </span></span></span><span style="font-size: 12.0pt; line-height: 107%;">Adults (&gt;40 kg): 3g IV calcium chloride should be administered following completion of each MTP cooler. </span>
- <span style="font-size: 12.0pt; line-height: 107%;">Pediatric patients (</span><span style="font-size: 12.0pt; line-height: 107%; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;">≤</span><span style="font-size: 12.0pt; line-height: 107%;">40 kg): 20 mg/kg IV calcium chloride should be administered after every 2 rounds of PRBC/FFP</span>

<span style="font-size: 12.0pt; line-height: 107%;">Anticoagulant Reversal</span>

- <span style="font-size: 12.0pt; line-height: 107%;">Injured patients in hemorrhagic shock with pre-existing anticoagulant use should be reversed with the appropriate reversal agent. See “Guidelines for Management of Bleeding in Patients Receiving Anticoagulation” (MP 11) for additional details. </span>

<span style="font-size: 12.0pt; line-height: 107%;">\*\*\*Please utilize Pharmacy for any questions regarding dosage and use of therapeutic adjuncts.\*\*\*</span>

<u><span style="font-size: 12.0pt; line-height: 107%;">Assessment of Coagulopathy and Transfusion Targets</span></u>

- <span style="font-size: 12.0pt; line-height: 107%;">Coagulopathy </span>
    - - <span style="font-size: 12.0pt; line-height: 107%;">Recommended initial lab testing at initiation of MTP include:</span>
            - - <span style="font-size: 12.0pt; line-height: 107%;">CBC, PT/PTT, INR, fibrinogen, ROTEM</span>
        - <span style="font-size: 12.0pt; line-height: 107%;">Ongoing lab testing during MTP include: </span>
            - - <span style="font-size: 12.0pt; line-height: 107%;">CBC, PT/PTT, INR, fibrinogen, and ROTEM every 4 hrs or as clinical situation indicates. </span>
        - <span style="font-size: 12.0pt; line-height: 107%;">ROTEM parameters</span>
            - - <span style="font-size: 12.0pt; line-height: 107%;">A5<sub>EXTEM </sub>&lt;35 mm OR ML </span><span style="font-size: 12.0pt; line-height: 107%; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;">≥ 5% (within 60 min) </span><span style="font-size: 12.0pt; line-height: 107%; font-family: Wingdings; mso-ascii-font-family: Calibri; mso-ascii-theme-font: minor-latin; mso-hansi-font-family: Calibri; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin; mso-char-type: symbol; mso-symbol-font-family: Wingdings;"><span style="mso-char-type: symbol; mso-symbol-font-family: Wingdings;">à</span></span><span style="font-size: 12.0pt; line-height: 107%; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;"> give TXA</span>
                - <span style="font-size: 12.0pt; line-height: 107%;">A5<sub>EXTEM </sub>&lt;35 mm AND A5<sub>FIBTEM</sub> &lt;9 mm </span><span style="font-size: 12.0pt; line-height: 107%; font-family: Wingdings; mso-ascii-font-family: Calibri; mso-ascii-theme-font: minor-latin; mso-hansi-font-family: Calibri; mso-hansi-theme-font: minor-latin; mso-char-type: symbol; mso-symbol-font-family: Wingdings;"><span style="mso-char-type: symbol; mso-symbol-font-family: Wingdings;">à</span></span><span style="font-size: 12.0pt; line-height: 107%;"> give cryoprecipitate </span>
                - <span style="font-size: 12.0pt; line-height: 107%;">A5<sub>EXTEM</sub> &lt;35 mm AND A5<sub>FIBTEM</sub> </span><span style="font-size: 12.0pt; line-height: 107%; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;">≥9</span><span style="font-size: 12.0pt; line-height: 107%;"> mm</span><span style="font-size: 12.0pt; line-height: 107%; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;"> </span><span style="font-size: 12.0pt; line-height: 107%; font-family: Wingdings; mso-ascii-font-family: Calibri; mso-ascii-theme-font: minor-latin; mso-hansi-font-family: Calibri; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin; mso-char-type: symbol; mso-symbol-font-family: Wingdings;"><span style="mso-char-type: symbol; mso-symbol-font-family: Wingdings;">à</span></span><span style="font-size: 12.0pt; line-height: 107%; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;"> give platelets </span>
                - <span style="font-size: 12.0pt; line-height: 107%;">CT<sub>EXTEM</sub> &gt;80 s AND A5<sub>FIBTEM</sub> </span><span style="font-size: 12.0pt; line-height: 107%; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;">≥9</span><span style="font-size: 12.0pt; line-height: 107%;"> mm <span style="mso-spacerun: yes;"> </span></span><span style="font-size: 12.0pt; line-height: 107%; font-family: Wingdings; mso-ascii-font-family: Calibri; mso-ascii-theme-font: minor-latin; mso-hansi-font-family: Calibri; mso-hansi-theme-font: minor-latin; mso-char-type: symbol; mso-symbol-font-family: Wingdings;"><span style="mso-char-type: symbol; mso-symbol-font-family: Wingdings;">à</span></span><span style="font-size: 12.0pt; line-height: 107%;"> Give PCC or plasma </span>
                - <span style="font-size: 12.0pt; line-height: 107%;">CT<sub>INTEM </sub>&gt; 240 s AND (<sub> </sub>CT<sub>INTEM</sub>/CT<sub>HEPTEM</sub>) &gt; 1.25 </span><span style="font-size: 12.0pt; line-height: 107%; font-family: Wingdings; mso-ascii-font-family: Calibri; mso-ascii-theme-font: minor-latin; mso-hansi-font-family: Calibri; mso-hansi-theme-font: minor-latin; mso-char-type: symbol; mso-symbol-font-family: Wingdings;"><span style="mso-char-type: symbol; mso-symbol-font-family: Wingdings;">à</span></span><span style="font-size: 12.0pt; line-height: 107%;"> give protamine, if suspected heparin activity or heparin like effects <span style="mso-spacerun: yes;"> </span></span>
                - <span style="font-size: 12.0pt; line-height: 107%;">CT<sub>INTEM </sub>&gt; 240 s AND (<sub> </sub>CT<sub>INTEM</sub>/CT<sub>HEPTEM</sub>) &lt; 1.25 <span style="mso-spacerun: yes;"> </span></span><span style="font-size: 12.0pt; line-height: 107%; font-family: Wingdings; mso-ascii-font-family: Calibri; mso-ascii-theme-font: minor-latin; mso-hansi-font-family: Calibri; mso-hansi-theme-font: minor-latin; mso-char-type: symbol; mso-symbol-font-family: Wingdings;"><span style="mso-char-type: symbol; mso-symbol-font-family: Wingdings;">à</span></span><span style="font-size: 12.0pt; line-height: 107%;"> give plasma</span>

- <span style="font-size: 12.0pt; line-height: 107%; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><span style="mso-list: Ignore;"><span style="font: 7.0pt 'Times New Roman';"> </span></span></span><span style="font-size: 12.0pt; line-height: 107%;">Acidosis </span>
    - - <span style="font-size: 12.0pt; line-height: 107%;">Goal: Lactic Acid &lt; 2</span>
        - <span style="font-size: 12.0pt; line-height: 107%;">Goal: Base Deficit &lt;4</span>
        - <span style="font-size: 12.0pt; line-height: 107%;">Ongoing lab testing: Lactic acid and arterial blood gas (ABG) to assess acid-base status every 6 hrs during MTP or as clinical situation indicates.</span>

- <span style="font-size: 12.0pt; line-height: 107%;">Hypothermia</span>
    - - <span style="font-size: 12.0pt; line-height: 107%;">Goal: 36</span><span style="font-size: 12.0pt; line-height: 107%; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;"> degrees Celsius or warmer</span>
        - <span style="font-size: 12.0pt; line-height: 107%; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;">All trauma patients should undergo passive external rewarming including warmed blankets and increased ambient room temperature</span>
        - <span style="font-size: 12.0pt; line-height: 107%; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;">Administer warm blood products</span>
        - <span style="font-size: 12.0pt; line-height: 107%; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;">Continuously monitor utilizing core temperature probe.</span>

- <span style="font-size: 12.0pt; line-height: 107%; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;">Hypocalcemia </span>
    - - <span style="font-size: 12.0pt; line-height: 107%; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;">Goal: ionized calcium (iCa) &gt;1.0 mmol/L</span>
        - <span style="font-size: 12.0pt; line-height: 107%; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;">Ongoing testing: iCa should be monitored at initiation of MTP and after completion of each MTP cooler. </span><span style="font-size: 12.0pt; line-height: 107%;"><span style="mso-spacerun: yes;"> </span></span>

- <span style="font-size: 12.0pt; line-height: 107%;">Hyperkalemia </span>
    - - <span style="font-size: 12.0pt; line-height: 107%;">Goal: potassium &lt;5</span>
        - <span style="font-size: 12.0pt; line-height: 107%;">Ongoing lab testing: Potassium every 6 hours or as clinical situation indicates. </span>

<u><span style="font-size: 12.0pt; line-height: 107%;">Discontinuation and Transition to Goal Directed Therapy</span></u>

- <span style="font-size: 12.0pt; line-height: 107%;">Ratio-driven massive transfusion may be discontinued and transitioned to goal-directed transfusion based on laboratory findings if surgical bleeding has been controlled or there is radiographic and physiologic evidence of bleeding control after embolization. </span>
- <span style="font-size: 12.0pt; line-height: 107%;">MTP may also be discontinued when there is recognition that further resuscitation is futile. </span>
- <span style="font-size: 12.0pt; line-height: 107%;">Suggested values for Goal Directed Therapy:</span>
    - - <span style="font-size: 12.0pt; line-height: 107%;">Hemoglobin </span><span style="font-size: 12.0pt; line-height: 107%; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;">≥</span><span style="font-size: 12.0pt; line-height: 107%;"> 10g/dL</span>
        - <span style="font-size: 12.0pt; line-height: 107%;">Platelets &gt;150,000/mcL</span>
        - <span style="font-size: 12.0pt; line-height: 107%;">PT &lt;18 seconds</span>
        - <span style="font-size: 12.0pt; line-height: 107%;">PTT &lt; 35 seconds</span>
        - <span style="font-size: 12.0pt; line-height: 107%;">INR &lt;1.5</span>
        - <span style="font-size: 12.0pt; line-height: 107%;">Fibrinogen &gt;180</span>
        - <span style="font-size: 12.0pt; line-height: 107%;">ROTEM</span>
            - - <span style="font-size: 12.0pt; line-height: 107%;">Clotting time (CT) – CT<sub>IN</sub>&lt;215 and CT<sub>EX</sub>&lt;75</span>
                - <span style="font-size: 12.0pt; line-height: 107%;">Amplitude 5 min after CT (A5)—A5<sub>IN,EX</sub>&gt;33</span>
                - <span style="font-size: 12.0pt; line-height: 107%;">Amplitude 10 min after CT (A10)—A10<sub>IN,EX</sub>&gt;45</span>
                - <span style="font-size: 12.0pt; line-height: 107%;">Maximum clot firmness (MCF)—MCF<sub>IN,EX</sub>&gt;56 and MCF<sub>FIB</sub>&gt;5</span>
                - <span style="font-size: 12.0pt; line-height: 107%;">Maximum Lysis (ML)—ML<sub>IN,EX,FIB</sub>&lt;7%</span>

#### Outcome Measures and Guideline Adherance

<span style="mso-bidi-font-weight: bold;">All trauma massive transfusion activations will be monitored through the trauma performance improvement (PI) process. Specific indicators that will be monitored/assessed include:</span>

1. <span style="mso-bidi-font-weight: bold;">Time from initiation of MTP to infusion of the first unit PRBCs</span>
2. <span style="mso-bidi-font-weight: bold;">Time from initiation of MTP to infusion of the first unit of plasma</span>
3. <span style="mso-bidi-font-weight: bold;">Overall ration of blood product transfusion and at 2 hours</span>
4. <span style="mso-bidi-font-weight: bold;">Total blood products used from MTP activation to 24 hours</span>
5. <span style="mso-bidi-font-weight: bold;">Notifying blood bank within 1 hour of MTP termination</span>
6. <span style="mso-bidi-font-weight: bold;">Use of therapeutic adjuncts</span>
7. <span style="mso-bidi-font-weight: bold;">Complications <span style="mso-spacerun: yes;"> </span></span>

#### Related Policies:

- TX36 Massive Transfusion/Severe Coagulopathy
- MP 11 Guidelines for Management of Bleeding in Patients Receiving Anticoagulation

#### Key Contributors

- Emily Cantrell, MD <span style="mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;">| Division of Acute Care Surgery, Faculty | Principle Author </span>
- Abby Josef, MD <span style="mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;">| Division of Acute Care Surgery, Faculty | Author </span>

#### References

1. **<span style="mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;"><span style="mso-list: Ignore;"><span style="font: 7.0pt 'Times New Roman';"> </span></span></span>**<span style="mso-bidi-font-weight: bold;">American College of Surgeons Trauma Quality Improvement Program. (2015) *ACS TQIP Massive Transfusion in Trauma Guidelines.* Retrieved from </span>[transfusion\_guildelines.pdf (facs.org)](https://www.facs.org/media/zcjdtrd1/transfusion_guildelines.pdf)
2. American College of Surgeons Advanced Trauma Life Support, 10<sup>th</sup> Ed. 2018.
3. Callcut RA, Cotton B, Mskat P, Fox EE, Wade CE, Holcomb JB, Robinson RH. (2013) Defining when to initiate massive transfusion (MT): A validation study of individual massive transfusion triggers in PROMMTT patients. *J Trauma Acute Care Surg.*74(1), 59-67.
4. Schroll R, Swift D, Tatum D, Courch S, Heaney JB, Llado-Farulla M, Zucker S, Gill F, Brown G, Buffin N, Duchesne J. Accuracy of shock index versus ABC score to predict need for massive transfusion in trauma patients. *Injury*. 49(1), 15-19.
5. Napolitano LM, Cohen MJ, Cotton BA, Schreiber MA, Moore EE (2013). Tranexamic acid in trauma: How we should us it? *J Trauma Acute Care Surg*. 74(6), 1575-1586.
6. Nunez TC, Voskrensensky IV, Dossett LA, Shinal R, Dutton WD, Cotton BA. (2009) Early prediction of massive transfusion in trauma: Simple as ABC (assessment of blood consumption)? *J Trauma: Injury, Infection, and Critical Care.* 66, 346-352.
7. Panteli M, Pountos I, Giannoudis PV. (2016) Pharmacological adjuncts to stop bleeding: Options and effectiveness. *Eur J Trauma and Em Surg.* 42, 303-310.
8. Stettler GR, Moore EE, Nunns GR, Chandler J, Peltz E, Silliman CC, Banerjee A, Sauaia A. (2018) Rotational thromboelastometry thresholds for patients at risk for massive transfusion. *J Surg Res*. 228: 154-159.
9. Chidester SJ, Williams N, Wang W, Groner JI. (2012) A pediatric massive transfusion protocol. *J Trauma Acute Care Surg*. 73(5), 1273-1277.
10. Eckert MJ, Wertin TM, Tyner SD, Nelson DW, Martin MJ. (2014) Tranexamic acid administration to pediatric trauma patients in a combat setting: The pediatric trauma and tranexamic acid study (PED-TRAX). *J Trauma Acute Care Surg.* 77(6), 852-858.
11. Neff LP, Cannon JW, Morrison JJ, Edwards MJ, Spinella PC, Borgman MA. (2015) clearly defining pediatric massive transfusion: Cutting through the fog and friction with combat data. *J Trauma Acute Care Surg.* 78(1), 22-29.

#### Last updated:

May, 2024

# REBOA Instructions

This page is intended to serve as a quick reference for easy access to the REBOA kit instructions. The information and images are directly from the insertion instructions, and were obtained from [http://prytimemedical.com/wp-content/uploads/2017/08/ER-REBOA-Catheter-Quick-Reference-Guide-wall-poster.pdf](http://prytimemedical.com/wp-content/uploads/2017/08/ER-REBOA-Catheter-Quick-Reference-Guide-wall-poster.pdf)

[![image.png](https://paths.trauma.ai/uploads/images/gallery/2023-08/scaled-1680-/W5Cimage.png)](https://paths.trauma.ai/uploads/images/gallery/2023-08/W5Cimage.png)

[![image.png](https://paths.trauma.ai/uploads/images/gallery/2023-08/scaled-1680-/Mmdimage.png)](https://paths.trauma.ai/uploads/images/gallery/2023-08/Mmdimage.png)

[![image.png](https://paths.trauma.ai/uploads/images/gallery/2023-08/scaled-1680-/mPzimage.png)](https://paths.trauma.ai/uploads/images/gallery/2023-08/mPzimage.png)

[![image.png](https://paths.trauma.ai/uploads/images/gallery/2023-08/scaled-1680-/XxVimage.png)](https://paths.trauma.ai/uploads/images/gallery/2023-08/XxVimage.png)

[![image.png](https://paths.trauma.ai/uploads/images/gallery/2023-08/scaled-1680-/fRrimage.png)](https://paths.trauma.ai/uploads/images/gallery/2023-08/fRrimage.png)

# Whole Blood Usage in Trauma

#### **Purpose:**

The implementation of a whole blood program at Nebraska Medicine is designed to optimize our resuscitation practices for the hemorrhaging trauma patient. Whole blood, specifically Low Titer O Whole Blood (LTOWB) immediately delivers a balanced product with less preservative than individual components. It also has the advantage of being more convenient by giving one product instead of three to achieve a balanced transfusion ratio. The goal of this document is to standardize the management of resuscitation with LTOWB for hemorrhagic shock from a traumatic mechanism. <span style="mso-spacerun: yes;"> </span>

#### **Definitions:** 

<span style="text-decoration: underline;">Low Titer O Whole Blood (LTOWB):</span> a complete blood product that contains Type O red blood cells, plasma and platelets. It contains low levels of antibodies making it safe to transfuse to a patient with any blood type. Additionally, LTOWB contains less preservative than its respective components.

#### **Protocol:**

<span style="mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;"><span style="mso-list: Ignore;">1.<span style="font: 7.0pt 'Times New Roman';"> </span></span></span>This protocol may be initiated in the Trauma Bay in the Emergency Department of Nebraska Medicine for trauma patients only

<span style="mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;"><span style="mso-list: Ignore;">2.<span style="font: 7.0pt 'Times New Roman';"> </span></span></span>Whole Blood transfusion can only be activated by the attending physician or their surrogate

<span style="mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;"><span style="mso-list: Ignore;">3.<span style="font: 7.0pt 'Times New Roman';"> </span></span></span>Patients who meet the following criteria are eligible to receive LTOWB

<span style="mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;"><span style="mso-list: Ignore;">a.<span style="font: 7.0pt 'Times New Roman';"> </span></span></span>Patient is a male or female 6 years of age or older

<span style="mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;"><span style="mso-list: Ignore;">b.<span style="font: 7.0pt 'Times New Roman';"> </span></span></span>Patient has significant and potentially life-threatening bleeding

<span style="mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;"><span style="mso-list: Ignore;">c.<span style="font: 7.0pt 'Times New Roman';"> </span></span></span>Anticipated need for massive transfusion protocol (MTP)

<span style="mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;"><span style="mso-list: Ignore;">4.<span style="font: 7.0pt 'Times New Roman';"> </span></span></span>Once a patient has been deemed eligible and the decision to transfuse LTOWB has been made, the attending physician or their surrogate will direct the ED nurse to begin the transfusion process in accordance with the established MTP/Severe Coagulopathy/Emergency Release Blood Administration Policy (TX 36)

<span style="mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;"><span style="mso-list: Ignore;">5.<span style="font: 7.0pt 'Times New Roman';"> </span></span></span>After having been deemed eligible to receive LTOWB, a patient may receive a maximum of two units

<span style="mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;"><span style="mso-list: Ignore;">6.<span style="font: 7.0pt 'Times New Roman';"> </span></span></span>Once a patient receives two units of LTOWB, the MTP should proceed in the usual manner, if indicated

<span style="mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;"><span style="mso-list: Ignore;">7.<span style="font: 7.0pt 'Times New Roman';"> </span></span></span>Whole blood transfusion initiated in the Trauma Bay may be continued in other patient care areas such as the operating room, interventional radiology, or the intensive care unit

<span style="mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;"><span style="mso-list: Ignore;">8.<span style="font: 7.0pt 'Times New Roman';"> </span></span></span>All other aspects of transfusion should proceed per established protocols

<span style="mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;"><span style="mso-list: Ignore;">9.<span style="font: 7.0pt 'Times New Roman';"> </span></span></span>No additional testing is required following administration of LTOWB as the risk of transfusion reaction and hemolysis is thought to be similar to risks associated with uncrossmatched transfusions

#### **FAQ:**

Can LTOWB be used for non-traumatic patients?

- No, not at this time.<span style="mso-spacerun: yes;"> </span>Trauma pilot will run from Nov 2021 to April 2022, then will review for utilization and cost effectiveness.

<span style="mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;"><span style="mso-list: Ignore;">2.<span style="font: 7.0pt 'Times New Roman';"> </span></span></span>How do I report blood transfused?

- Report LTOWB units separately.<span style="mso-spacerun: yes;"> </span>For example: 2 u LTOWB, 5 pRBCs, 5 FFP, 1 plts

<span style="mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;"><span style="mso-list: Ignore;">3.<span style="font: 7.0pt 'Times New Roman';"> </span></span></span>Turn around time after utilization of the 2 u LTOWB in the trauma bay fridge?

- About 2 weeks

<span style="mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;"><span style="mso-list: Ignore;">4.<span style="font: 7.0pt 'Times New Roman';"> </span></span></span>Do I need additional labs or studies before or after giving LTOWB?

- No, just a T &amp; S within 10 min of accessing the product

<span style="mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;"><span style="mso-list: Ignore;">5.<span style="font: 7.0pt 'Times New Roman';"> </span></span></span>When does LTOWB expire?

- 3 week topic life after collection, so will be stored in fridge for 2 weeks, then reprocessed

<span style="mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;"><span style="mso-list: Ignore;">6.<span style="font: 7.0pt 'Times New Roman';"> </span></span></span>Can I give more than 2 units LTOWB?

- No, the 2 units are a bridge to MTP.

[![embedded-image-PBRiSyhC.png](https://paths.trauma.ai/uploads/images/gallery/2023-06/scaled-1680-/embedded-image-pbrisyhc.png)](https://paths.trauma.ai/uploads/images/gallery/2023-06/embedded-image-pbrisyhc.png)

# Trauma Bay Adult Acute Agitation Management

**Purpose**:

Traumatically injured patients presenting to the emergency department (ED) experiencing acute agitation have the potential to harm themselves, hospital staff, and others. Safe and expeditious management of agitation is imperative to prevent potential further harm. However, treatment of acute agitation is challenging due to the heterogenicity of the patient population, cause or source of agitation, and the available therapeutic treatment options.

There are two critical factors that are essential to the management of agitation – early recognition and targeted intervention to the etiology driving the patient’s acutely agitated state. This treatment protocol is designed to help streamline the care of this difficult patient population.

**Background/Definitions**:

Acutely agitated and/or violent behaviors displayed by trauma patients interfere with the required medical care of the patient. Acute agitation is a medical emergency. Determining the cause or causes of agitation will allow for a more informed management strategy for the patient. However, because of constraints on time, limited information, and lack of patient engagement, one must assess and identify the underlying cause(s) expeditiously. The goal of acute agitation treatment is to calm the patient in the least invasive way, without causing oversedation.

Per policy TX-1, the philosophy of Nebraska Medicine is to reduce/limit the use of physical and chemical restraint while maintaining the safety and preserving dignity, rights, and wellbeing of patients. Nebraska Medicine respects the patient’s right to be free of restraints of any form that are not medically necessary. If a patient’s condition necessitates the use of restraints, the safety and wellbeing of the patient and medical staff caring for the patient is the primary focus of the medical team.

<span style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><u><span style="mso-fareast-font-family: 'Times New Roman';">Severe Agitation</span></u><span style="mso-fareast-font-family: 'Times New Roman';">: </span>

<span style="font-family: 'Courier New'; mso-fareast-font-family: 'Courier New';"><span style="mso-list: Ignore;">o<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><span style="mso-fareast-font-family: 'Times New Roman';">Currently violent or aggressive, attacking people and/or objects.</span>

<span style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><u><span style="mso-fareast-font-family: 'Times New Roman';">Moderate Agitation</span></u><span style="mso-fareast-font-family: 'Times New Roman';">: </span>

<span style="font-family: 'Courier New'; mso-fareast-font-family: 'Courier New';"><span style="mso-list: Ignore;">o<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><span style="mso-fareast-font-family: 'Times New Roman';">Physically or verbally threatening, difficult to redirect, extremely active, however, not violent. </span>

<span style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><u><span style="mso-fareast-font-family: 'Times New Roman';">Mild Agitation</span></u><span style="mso-fareast-font-family: 'Times New Roman';">: </span>

<span style="font-family: 'Courier New'; mso-fareast-font-family: 'Courier New';"><span style="mso-list: Ignore;">o<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><span style="mso-fareast-font-family: 'Times New Roman';">Signs of overt physical or verbal activity but redirectable. </span>

<span style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><u><span style="mso-fareast-font-family: 'Times New Roman';">De-escalation</span></u><span style="mso-fareast-font-family: 'Times New Roman';">: </span>

<span style="font-family: 'Courier New'; mso-fareast-font-family: 'Courier New';"><span style="mso-list: Ignore;">o<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><span style="mso-fareast-font-family: 'Times New Roman';">A combination of both verbal and nonverbal strategies intended to calm the patient down to cooperate with their care.</span>

<span style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><u><span style="mso-fareast-font-family: 'Times New Roman';">Sedation and Analgesia</span></u><span style="mso-fareast-font-family: 'Times New Roman';">: </span>

<span style="font-family: 'Courier New'; mso-fareast-font-family: 'Courier New';"><span style="mso-list: Ignore;">o<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><span style="mso-fareast-font-family: 'Times New Roman';">Use of pharmacologic agents to create a drug-induced state to reduce physiologic and psychological stress to a patient undergoing medical, surgical, or diagnostic procedures.</span>

Common Medical Causes of Acute Agitation

<div class="WordSection1" id="bkmrk-type-examples-neurol"><div class="WordSection1"><table border="0" cellpadding="0" cellspacing="0" class="MsoNormalTable" style="border-collapse: collapse; mso-yfti-tbllook: 1184; mso-padding-alt: 0in 0in 0in 0in;"><tbody><tr style="mso-yfti-irow: 0; mso-yfti-firstrow: yes;"><td style="width: 233.75pt; border: solid #999999 1.0pt; border-bottom: solid #666666 1.5pt; padding: 0in 5.4pt 0in 5.4pt;" valign="top" width="312">**Type**

</td><td style="width: 436.35pt; border-top: solid #999999 1.0pt; border-left: none; border-bottom: solid #666666 1.5pt; border-right: solid #999999 1.0pt; padding: 0in 5.4pt 0in 5.4pt;" valign="top" width="582">**Examples**

</td></tr><tr style="mso-yfti-irow: 1;"><td style="width: 233.75pt; border: solid #999999 1.0pt; border-top: none; padding: 0in 5.4pt 0in 5.4pt;" valign="top" width="312">**Neurological**

</td><td style="width: 436.35pt; border-top: none; border-left: none; border-bottom: solid #999999 1.0pt; border-right: solid #999999 1.0pt; padding: 0in 5.4pt 0in 5.4pt;" valign="top" width="582">Traumatic brain injury, intracranial hemorrhage, seizure/post-ictal, stroke, encephalopathy

</td></tr><tr style="mso-yfti-irow: 2;"><td style="width: 233.75pt; border: solid #999999 1.0pt; border-top: none; padding: 0in 5.4pt 0in 5.4pt;" valign="top" width="312">**Infectious**

</td><td style="width: 436.35pt; border-top: none; border-left: none; border-bottom: solid #999999 1.0pt; border-right: solid #999999 1.0pt; padding: 0in 5.4pt 0in 5.4pt;" valign="top" width="582">Meningitis, sepsis, urinary tract infection (elderly)

</td></tr><tr style="mso-yfti-irow: 3;"><td style="width: 233.75pt; border: solid #999999 1.0pt; border-top: none; padding: 0in 5.4pt 0in 5.4pt;" valign="top" width="312">**Metabolic**

</td><td style="width: 436.35pt; border-top: none; border-left: none; border-bottom: solid #999999 1.0pt; border-right: solid #999999 1.0pt; padding: 0in 5.4pt 0in 5.4pt;" valign="top" width="582">Electrolyte disturbance, hypoglycemia

</td></tr><tr style="mso-yfti-irow: 4;"><td style="width: 233.75pt; border: solid #999999 1.0pt; border-top: none; padding: 0in 5.4pt 0in 5.4pt;" valign="top" width="312">**Respiratory**

</td><td style="width: 436.35pt; border-top: none; border-left: none; border-bottom: solid #999999 1.0pt; border-right: solid #999999 1.0pt; padding: 0in 5.4pt 0in 5.4pt;" valign="top" width="582">Hypoxia

</td></tr><tr style="mso-yfti-irow: 5;"><td style="width: 233.75pt; border: solid #999999 1.0pt; border-top: none; padding: 0in 5.4pt 0in 5.4pt;" valign="top" width="312">**Toxicological**

</td><td style="width: 436.35pt; border-top: none; border-left: none; border-bottom: solid #999999 1.0pt; border-right: solid #999999 1.0pt; padding: 0in 5.4pt 0in 5.4pt;" valign="top" width="582">Environmental toxin, medication reaction, illicit drug use

</td></tr><tr style="mso-yfti-irow: 6;"><td style="width: 233.75pt; border: solid #999999 1.0pt; border-top: none; padding: 0in 5.4pt 0in 5.4pt;" valign="top" width="312">**Endocrine**

</td><td style="width: 436.35pt; border-top: none; border-left: none; border-bottom: solid #999999 1.0pt; border-right: solid #999999 1.0pt; padding: 0in 5.4pt 0in 5.4pt;" valign="top" width="582">Thyrotoxicosis, myxedema coma

</td></tr><tr style="mso-yfti-irow: 7; mso-yfti-lastrow: yes;"><td style="width: 233.75pt; border: solid #999999 1.0pt; border-top: none; padding: 0in 5.4pt 0in 5.4pt;" valign="top" width="312">**Other**

</td><td style="width: 436.35pt; border-top: none; border-left: none; border-bottom: solid #999999 1.0pt; border-right: solid #999999 1.0pt; padding: 0in 5.4pt 0in 5.4pt;" valign="top" width="582">Hyper- or hypothermia, acute pain

</td></tr></tbody></table>

</div></div>**Practice Recommendations for Medical Management**:

<span style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><span style="mso-fareast-font-family: 'Times New Roman';">De-escalation should always be attempted prior to medication management and physical restraint.</span>

<span style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><span style="mso-fareast-font-family: 'Times New Roman';">Restraint may only be imposed to ensure the immediate physical safety of the patient, staff or others and must be discontinued as soon as safely possible, regardless of the scheduled expiration of the order.</span>

<span style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><span style="mso-fareast-font-family: 'Times New Roman';">TX\_01 will be followed if/when restraint use is required. </span>

<span style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><span style="mso-fareast-font-family: 'Times New Roman';">Follow the management considerations, listed in the table below, using the preferred agent(s) as listed in Attachment A. Preferred agents show better clinical properties, including onset of action, efficacy, and lower incidence of adverse effects.</span>

Management Considerations for Agitation

<div class="WordSection1" id="bkmrk-severity-of-agitatio"><div class="WordSection1"><table border="0" cellpadding="0" cellspacing="0" class="MsoNormalTable" style="border-collapse: collapse; mso-yfti-tbllook: 1184; mso-padding-alt: 0in 0in 0in 0in;"><tbody><tr style="mso-yfti-irow: 0; mso-yfti-firstrow: yes;"><td style="width: 116.85pt; border: solid #999999 1.0pt; border-bottom: solid #666666 1.5pt; padding: 0in 5.4pt 0in 5.4pt;" valign="top" width="156">***Severity of Agitation***

</td><td style="width: 116.85pt; border-top: solid #999999 1.0pt; border-left: none; border-bottom: solid #666666 1.5pt; border-right: solid #999999 1.0pt; padding: 0in 5.4pt 0in 5.4pt;" valign="top" width="156">**Preferred Route of Administration**

</td><td style="width: 238.4pt; border-top: solid #999999 1.0pt; border-left: none; border-bottom: solid #666666 1.5pt; border-right: solid #999999 1.0pt; padding: 0in 5.4pt 0in 5.4pt;" valign="top" width="318">**Dosing Considerations**

</td><td style="width: 2.75in; border-top: solid #999999 1.0pt; border-left: none; border-bottom: solid #666666 1.5pt; border-right: solid #999999 1.0pt; padding: 0in 5.4pt 0in 5.4pt;" valign="top" width="264">**Special Populations**

</td></tr><tr style="mso-yfti-irow: 1;"><td style="width: 116.85pt; border: solid #999999 1.0pt; border-top: none; padding: 0in 5.4pt 0in 5.4pt;" valign="top" width="156">***Severe***

</td><td style="width: 116.85pt; border-top: none; border-left: none; border-bottom: solid #999999 1.0pt; border-right: solid #999999 1.0pt; padding: 0in 5.4pt 0in 5.4pt;" valign="top" width="156">IV, when able

IM, if IV not available

</td><td style="width: 238.4pt; border-top: none; border-left: none; border-bottom: solid #999999 1.0pt; border-right: solid #999999 1.0pt; padding: 0in 5.4pt 0in 5.4pt;" valign="top" width="318">Maximize dose of first agent used, allowing for the onset and effects of the previous dose prior to administering second dose

</td><td rowspan="3" style="width: 2.75in; border-top: none; border-left: none; border-bottom: solid #999999 1.0pt; border-right: solid #999999 1.0pt; padding: 0in 5.4pt 0in 5.4pt;" width="264">Dosing adjustments may be required for elderly, renally/hepatically impaired, and/or when given medication(s) prior to arrival.

Lower doses may be required when using concomitant sedating medications.

</td></tr><tr style="mso-yfti-irow: 2;"><td style="width: 116.85pt; border: solid #999999 1.0pt; border-top: none; padding: 0in 5.4pt 0in 5.4pt;" valign="top" width="156">***Moderate***

</td><td style="width: 116.85pt; border-top: none; border-left: none; border-bottom: solid #999999 1.0pt; border-right: solid #999999 1.0pt; padding: 0in 5.4pt 0in 5.4pt;" valign="top" width="156">IV, when able

IM, if IV not available

</td><td style="width: 238.4pt; border-top: none; border-left: none; border-bottom: solid #999999 1.0pt; border-right: solid #999999 1.0pt; padding: 0in 5.4pt 0in 5.4pt;" valign="top" width="318">Smaller doses may be sufficient (as compared to what is required for severe agitation)

If able/known, use a patient’s home regimen when patients can tolerate oral therapy.

</td></tr><tr style="mso-yfti-irow: 3; mso-yfti-lastrow: yes;"><td style="width: 116.85pt; border: solid #999999 1.0pt; border-top: none; padding: 0in 5.4pt 0in 5.4pt;" valign="top" width="156">***Mild***

</td><td style="width: 116.85pt; border-top: none; border-left: none; border-bottom: solid #999999 1.0pt; border-right: solid #999999 1.0pt; padding: 0in 5.4pt 0in 5.4pt;" valign="top" width="156">PO

</td><td style="width: 238.4pt; border-top: none; border-left: none; border-bottom: solid #999999 1.0pt; border-right: solid #999999 1.0pt; padding: 0in 5.4pt 0in 5.4pt;" valign="top" width="318">If able/known, use a patient’s home regimen when patients can tolerate oral therapy.

</td></tr></tbody></table>

</div></div>**Attachment A – Preferred Treatment Options for Acute Agitation (Trauma Bay)**

Preferred Treatment Options: \*

<div class="WordSection1" id="bkmrk-preferred-options-me"><div class="WordSection1"><table border="0" cellpadding="0" cellspacing="0" class="MsoNormalTable" style="width: 711.4pt; margin-left: -27.25pt; border-collapse: collapse; mso-yfti-tbllook: 1184; mso-padding-alt: 0in 0in 0in 0in;" width="949"><tbody><tr style="mso-yfti-irow: 0; mso-yfti-firstrow: yes;"><td rowspan="8" style="width: .75in; border-top: 2.25pt; border-left: 1.0pt; border-bottom: 2.25pt; border-right: 1.0pt; border-color: windowtext; border-style: solid; mso-border-top-alt: 2.25pt; mso-border-left-alt: .5pt; mso-border-bottom-alt: 2.25pt; mso-border-right-alt: 1.0pt; mso-border-color-alt: windowtext; mso-border-style-alt: solid; background: #E7E6E6; mso-background-themecolor: background2; padding: 0in 5.4pt 0in 5.4pt;" width="72">**<span style="font-size: 9.0pt; line-height: 105%; color: black;">Preferred</span>**

**<span style="font-size: 9.0pt; line-height: 105%; color: black;">Options</span>**

</td><td style="width: 78.65pt; border-top: solid windowtext 2.25pt; border-left: none; border-bottom: solid windowtext 2.25pt; border-right: solid windowtext 1.0pt; background: #E7E6E6; mso-background-themecolor: background2; padding: 0in 5.4pt 0in 5.4pt;" width="105">**<span style="font-size: 9.0pt; line-height: 105%; color: black; mso-color-alt: windowtext;">Medication</span>**

</td><td style="width: 65.35pt; border-top: solid windowtext 2.25pt; border-left: none; border-bottom: solid windowtext 2.25pt; border-right: solid windowtext 1.0pt; background: #E7E6E6; mso-background-themecolor: background2; padding: 0in 5.4pt 0in 5.4pt;" width="87">**<span style="font-size: 9.0pt; line-height: 105%; color: black; mso-color-alt: windowtext;">Dose</span>**

</td><td style="width: 76.5pt; border-top: solid windowtext 2.25pt; border-left: none; border-bottom: solid windowtext 2.25pt; border-right: solid windowtext 1.0pt; background: #E7E6E6; mso-background-themecolor: background2; padding: 0in 5.4pt 0in 5.4pt;" width="102">**<span style="font-size: 9.0pt; line-height: 105%; color: black; mso-color-alt: windowtext;">Soft Max</span>**

**<span style="font-size: 9.0pt; line-height: 105%; color: black; mso-color-alt: windowtext;">(Single Dose)</span>**

</td><td style="width: 1.0in; border-top: solid windowtext 2.25pt; border-left: none; border-bottom: solid windowtext 2.25pt; border-right: solid windowtext 1.0pt; background: #E7E6E6; mso-background-themecolor: background2; padding: 0in 5.4pt 0in 5.4pt;" width="96">**<span style="font-size: 9.0pt; line-height: 105%; color: black; mso-color-alt: windowtext;">Onset</span>**

</td><td style="width: 1.25in; border-top: solid windowtext 2.25pt; border-left: none; border-bottom: solid windowtext 2.25pt; border-right: solid windowtext 1.0pt; background: #E7E6E6; mso-background-themecolor: background2; padding: 0in 5.4pt 0in 5.4pt;" width="120">**<span style="font-size: 9.0pt; line-height: 105%; color: black; mso-color-alt: windowtext;">Time to Peak</span>**

</td><td style="width: 1.25in; border-top: solid windowtext 2.25pt; border-left: none; border-bottom: solid windowtext 2.25pt; border-right: solid windowtext 1.0pt; background: #E7E6E6; mso-background-themecolor: background2; padding: 0in 5.4pt 0in 5.4pt;" width="120">**<span style="font-size: 9.0pt; line-height: 105%; color: black; mso-color-alt: windowtext;">Duration</span>**

</td><td style="width: 184.9pt; border-top: solid windowtext 2.25pt; border-left: none; border-bottom: solid windowtext 2.25pt; border-right: solid windowtext 1.0pt; mso-border-top-alt: solid windowtext 2.25pt; mso-border-bottom-alt: solid windowtext 2.25pt; mso-border-right-alt: solid windowtext .5pt; background: #E7E6E6; mso-background-themecolor: background2; padding: 0in 5.4pt 0in 5.4pt;" width="247">**<span style="font-size: 9.0pt; line-height: 105%; color: black; mso-color-alt: windowtext;">Patient Considerations</span>**

</td></tr><tr style="mso-yfti-irow: 1; height: 1.15pt;"><td rowspan="2" style="width: 78.65pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; mso-border-top-alt: 2.25pt; mso-border-left-alt: 1.0pt; mso-border-bottom-alt: .5pt; mso-border-right-alt: .5pt; mso-border-color-alt: windowtext; mso-border-style-alt: solid; padding: 0in 5.4pt 0in 5.4pt; height: 1.15pt;" width="105"><span style="font-size: 9.0pt; line-height: 105%;">Midazolam</span>

</td><td style="width: 65.35pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; mso-border-top-alt: solid windowtext 2.25pt; mso-border-left-alt: solid windowtext .5pt; mso-border-alt: solid windowtext .5pt; padding: 0in 5.4pt 0in 5.4pt; height: 1.15pt;" width="87"><span style="font-size: 9.0pt; line-height: 105%;">2-5 mg IV</span>

</td><td style="width: 76.5pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; mso-border-top-alt: solid windowtext 2.25pt; mso-border-left-alt: solid windowtext .5pt; mso-border-alt: solid windowtext .5pt; padding: 0in 5.4pt 0in 5.4pt; height: 1.15pt;" width="102"><span style="font-size: 9.0pt; line-height: 105%;">5 mg IV</span>

</td><td style="width: 1.0in; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; mso-border-top-alt: solid windowtext 2.25pt; mso-border-left-alt: solid windowtext .5pt; mso-border-alt: solid windowtext .5pt; padding: 0in 5.4pt 0in 5.4pt; height: 1.15pt;" width="96"><span style="font-size: 9.0pt; line-height: 105%;">IV: 1-5 min</span>

</td><td style="width: 1.25in; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; mso-border-top-alt: solid windowtext 2.25pt; mso-border-left-alt: solid windowtext .5pt; mso-border-alt: solid windowtext .5pt; padding: 0in 5.4pt 0in 5.4pt; height: 1.15pt;" width="120"><span style="font-size: 9.0pt; line-height: 105%;">IV: 3-5 min</span>

</td><td style="width: 1.25in; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; mso-border-top-alt: solid windowtext 2.25pt; mso-border-left-alt: solid windowtext .5pt; mso-border-alt: solid windowtext .5pt; padding: 0in 5.4pt 0in 5.4pt; height: 1.15pt;" width="120"><span style="font-size: 9.0pt; line-height: 105%;">IV: 1-2 hours</span>

</td><td rowspan="2" style="width: 184.9pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; mso-border-top-alt: solid windowtext 2.25pt; mso-border-left-alt: solid windowtext .5pt; mso-border-alt: solid windowtext .5pt; padding: 0in 5.4pt 0in 5.4pt; height: 1.15pt;" width="247"><span style="font-size: 9.0pt; line-height: 105%;">Hypotension with larger doses (IV).</span>

<span style="font-size: 9.0pt; line-height: 105%;">Delayed onset of action (IM).</span>

</td></tr><tr style="mso-yfti-irow: 2; height: 1.1pt;"><td style="width: 65.35pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; mso-border-top-alt: solid windowtext .5pt; mso-border-left-alt: solid windowtext .5pt; mso-border-alt: solid windowtext .5pt; padding: 0in 5.4pt 0in 5.4pt; height: 1.1pt;" width="87"><span style="font-size: 9.0pt; line-height: 105%;">5-10 mg IM</span>

</td><td style="width: 76.5pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; mso-border-top-alt: solid windowtext .5pt; mso-border-left-alt: solid windowtext .5pt; mso-border-alt: solid windowtext .5pt; padding: 0in 0in 0in 0in; height: 1.1pt;" width="102"><span style="font-size: 9.0pt;">10 mg IM</span>

</td><td style="width: 1.0in; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; mso-border-top-alt: solid windowtext .5pt; mso-border-left-alt: solid windowtext .5pt; mso-border-alt: solid windowtext .5pt; padding: 0in 5.4pt 0in 5.4pt; height: 1.1pt;" width="96"><span style="font-size: 9.0pt; line-height: 105%;">IM: 15 min</span>

</td><td style="width: 1.25in; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; mso-border-top-alt: solid windowtext .5pt; mso-border-left-alt: solid windowtext .5pt; mso-border-alt: solid windowtext .5pt; padding: 0in 5.4pt 0in 5.4pt; height: 1.1pt;" width="120"><span style="font-size: 9.0pt; line-height: 105%;">IM: 30-60 min</span>

</td><td style="width: 1.25in; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; mso-border-top-alt: solid windowtext .5pt; mso-border-left-alt: solid windowtext .5pt; mso-border-alt: solid windowtext .5pt; padding: 0in 5.4pt 0in 5.4pt; height: 1.1pt;" width="120"><span style="font-size: 9.0pt; line-height: 105%;">IM: 1-2 hours</span>

</td></tr><tr style="mso-yfti-irow: 3; height: 42.3pt;"><td rowspan="2" style="width: 78.65pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; mso-border-top-alt: solid windowtext .5pt; mso-border-bottom-alt: solid windowtext .5pt; mso-border-right-alt: solid windowtext 1.0pt; padding: 0in 5.4pt 0in 5.4pt; height: 42.3pt;" width="105"><span style="font-size: 9.0pt; line-height: 105%;">Olanzapine</span>

</td><td style="width: 65.35pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; mso-border-top-alt: solid windowtext .5pt; padding: 0in 5.4pt 0in 5.4pt; height: 42.3pt;" width="87"><span style="font-size: 9.0pt; line-height: 105%;">2.5-5 mg IV</span>

</td><td style="width: 76.5pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; mso-border-top-alt: solid windowtext .5pt; mso-border-bottom-alt: solid windowtext .5pt; mso-border-right-alt: solid windowtext 1.0pt; padding: 0in 5.4pt 0in 5.4pt; height: 42.3pt;" width="102"><span style="font-size: 9.0pt; line-height: 105%;">5 mg IV</span>

</td><td style="width: 1.0in; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; mso-border-top-alt: solid windowtext .5pt; padding: 0in 5.4pt 0in 5.4pt; height: 42.3pt;" width="96"><span style="font-size: 9.0pt; line-height: 105%;">IV: 5-10 min</span>

</td><td rowspan="2" style="width: 1.25in; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; mso-border-top-alt: solid windowtext .5pt; mso-border-bottom-alt: solid windowtext .5pt; mso-border-right-alt: solid windowtext 1.0pt; padding: 0in 5.4pt 0in 5.4pt; height: 42.3pt;" width="120"><span style="font-size: 9.0pt; line-height: 105%;">15-45 min</span>

</td><td rowspan="2" style="width: 1.25in; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; mso-border-top-alt: solid windowtext .5pt; mso-border-bottom-alt: solid windowtext .5pt; mso-border-right-alt: solid windowtext 1.0pt; padding: 0in 5.4pt 0in 5.4pt; height: 42.3pt;" width="120"><span style="font-size: 9.0pt; line-height: 105%;">2 hours</span>

</td><td rowspan="2" style="width: 184.9pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; mso-border-top-alt: solid windowtext .5pt; mso-border-bottom-alt: solid windowtext .5pt; mso-border-right-alt: solid windowtext .5pt; padding: 0in 5.4pt 0in 5.4pt; height: 42.3pt;" width="247"><span style="font-size: 9.0pt; line-height: 105%;">Possible hypotension and respiratory depression with IV use.</span>

<span style="font-size: 9.0pt; line-height: 105%;">Caution when used with benzodiazepines due to risk of over-sedation.</span>

<span style="font-size: 9.0pt; line-height: 105%;">MAX 30 mg/24 hrs </span>

<span style="font-size: 9.0pt; line-height: 105%;">(Cumulative for all routes of administration)</span>

</td></tr><tr style="mso-yfti-irow: 4; height: 1.1pt;"><td style="width: 65.35pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; mso-border-bottom-alt: solid windowtext .5pt; mso-border-right-alt: solid windowtext 1.0pt; padding: 0in 5.4pt 0in 5.4pt; height: 1.1pt;" width="87"><span style="font-size: 9.0pt; line-height: 105%;">10 mg IM</span>

</td><td style="width: 76.5pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; mso-border-top-alt: solid windowtext .5pt; mso-border-bottom-alt: solid windowtext .5pt; mso-border-right-alt: solid windowtext 1.0pt; padding: 0in 0in 0in 0in; height: 1.1pt;" width="102"><span style="font-size: 9.0pt;">10 mg IM</span>

</td><td style="width: 1.0in; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; mso-border-bottom-alt: solid windowtext .5pt; mso-border-right-alt: solid windowtext 1.0pt; padding: 0in 5.4pt 0in 5.4pt; height: 1.1pt;" width="96"><span style="font-size: 9.0pt; line-height: 105%;">IM: 15 min</span>

</td></tr><tr style="mso-yfti-irow: 5; height: 1.15pt;"><td rowspan="2" style="width: 78.65pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; mso-border-top-alt: solid windowtext .5pt; mso-border-left-alt: solid windowtext .5pt; mso-border-alt: solid windowtext .5pt; padding: 0in 5.4pt 0in 5.4pt; height: 1.15pt;" width="105"><span style="font-size: 9.0pt; line-height: 105%;">Haloperidol</span>

</td><td rowspan="2" style="width: 65.35pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; mso-border-top-alt: solid windowtext .5pt; mso-border-left-alt: solid windowtext .5pt; mso-border-alt: solid windowtext .5pt; padding: 0in 5.4pt 0in 5.4pt; height: 1.15pt;" width="87"><span style="font-size: 9.0pt; line-height: 105%;">5 mg IV/IM</span>

</td><td rowspan="2" style="width: 76.5pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; mso-border-top-alt: solid windowtext .5pt; mso-border-left-alt: solid windowtext .5pt; mso-border-alt: solid windowtext .5pt; padding: 0in 5.4pt 0in 5.4pt; height: 1.15pt;" width="102"><span style="font-size: 9.0pt; line-height: 105%;">5 mg</span>

</td><td style="width: 1.0in; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; mso-border-top-alt: solid windowtext .5pt; mso-border-left-alt: solid windowtext .5pt; mso-border-alt: solid windowtext .5pt; padding: 0in 5.4pt 0in 5.4pt; height: 1.15pt;" width="96"><span style="font-size: 9.0pt; line-height: 105%;">IV: 3-20 min</span>

</td><td style="width: 1.25in; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; mso-border-top-alt: solid windowtext .5pt; mso-border-left-alt: solid windowtext .5pt; mso-border-alt: solid windowtext .5pt; padding: 0in 5.4pt 0in 5.4pt; height: 1.15pt;" width="120"><span style="font-size: 9.0pt; line-height: 105%;">IV: 30 min</span>

</td><td rowspan="2" style="width: 1.25in; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; mso-border-top-alt: solid windowtext .5pt; mso-border-left-alt: solid windowtext .5pt; mso-border-alt: solid windowtext .5pt; mso-border-right-alt: solid windowtext 1.0pt; padding: 0in 5.4pt 0in 5.4pt; height: 1.15pt;" width="120"><span style="font-size: 9.0pt; line-height: 105%;">2-4 hours</span>

</td><td rowspan="2" style="width: 184.9pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; mso-border-top-alt: solid windowtext .5pt; mso-border-bottom-alt: solid windowtext .5pt; mso-border-right-alt: solid windowtext .5pt; padding: 0in 5.4pt 0in 5.4pt; height: 1.15pt;" width="247"><span style="font-size: 9.0pt; line-height: 105%;">Risk of EKG changes</span>

<span style="font-size: 9.0pt; line-height: 105%;">Can lower seizure threshold </span>

</td></tr><tr style="mso-yfti-irow: 6; height: 1.1pt;"><td style="width: 1.0in; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; mso-border-top-alt: solid windowtext .5pt; mso-border-left-alt: solid windowtext .5pt; mso-border-alt: solid windowtext .5pt; padding: 0in 5.4pt 0in 5.4pt; height: 1.1pt;" width="96"><span style="font-size: 9.0pt; line-height: 105%;">IM: 15 min</span>

</td><td style="width: 1.25in; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; mso-border-top-alt: solid windowtext .5pt; mso-border-left-alt: solid windowtext .5pt; mso-border-alt: solid windowtext .5pt; padding: 0in 5.4pt 0in 5.4pt; height: 1.1pt;" width="120"><span style="font-size: 9.0pt; line-height: 105%;">IM: 20-30 min</span>

</td></tr><tr style="mso-yfti-irow: 7; mso-yfti-lastrow: yes; height: 1.15pt;"><td style="width: 78.65pt; border-top: none; border-left: none; border-bottom: solid windowtext 2.25pt; border-right: solid windowtext 1.0pt; mso-border-top-alt: solid windowtext .5pt; mso-border-bottom-alt: solid windowtext 2.25pt; mso-border-right-alt: solid windowtext .5pt; padding: 0in 5.4pt 0in 5.4pt; height: 1.15pt;" width="105"><span style="font-size: 9.0pt; line-height: 105%;">Dexmedetomidine</span>

</td><td style="width: 65.35pt; border-top: none; border-left: none; border-bottom: solid windowtext 2.25pt; border-right: solid windowtext 1.0pt; mso-border-top-alt: solid windowtext .5pt; mso-border-left-alt: solid windowtext .5pt; mso-border-alt: solid windowtext .5pt; mso-border-bottom-alt: solid windowtext 2.25pt; padding: 0in 5.4pt 0in 5.4pt; height: 1.15pt;" width="87"><span style="font-size: 9.0pt; line-height: 105%;">0.1-0.7 mcg/kg/hr IV, titrate to response</span>

</td><td style="width: 76.5pt; border-top: none; border-left: none; border-bottom: solid windowtext 2.25pt; border-right: solid windowtext 1.0pt; mso-border-top-alt: solid windowtext .5pt; mso-border-left-alt: solid windowtext .5pt; mso-border-alt: solid windowtext .5pt; mso-border-bottom-alt: solid windowtext 2.25pt; padding: 0in 5.4pt 0in 5.4pt; height: 1.15pt;" width="102"><span style="font-size: 9.0pt; line-height: 105%;">MAX rate </span>

<span style="font-size: 9.0pt; line-height: 105%;">0.7 mcg/kg/hr IV</span>

</td><td style="width: 1.0in; border-top: none; border-left: none; border-bottom: solid windowtext 2.25pt; border-right: solid windowtext 1.0pt; mso-border-top-alt: solid windowtext .5pt; mso-border-left-alt: solid windowtext .5pt; mso-border-alt: solid windowtext .5pt; mso-border-bottom-alt: solid windowtext 2.25pt; padding: 0in 5.4pt 0in 5.4pt; height: 1.15pt;" width="96"><span style="font-size: 9.0pt; line-height: 105%;">5-15 min</span>

</td><td style="width: 1.25in; border-top: none; border-left: none; border-bottom: solid windowtext 2.25pt; border-right: solid windowtext 1.0pt; mso-border-top-alt: solid windowtext .5pt; mso-border-left-alt: solid windowtext .5pt; mso-border-alt: solid windowtext .5pt; mso-border-bottom-alt: solid windowtext 2.25pt; padding: 0in 5.4pt 0in 5.4pt; height: 1.15pt;" width="120"><span style="font-size: 9.0pt; line-height: 105%;">60 min</span>

</td><td style="width: 1.25in; border-top: none; border-left: none; border-bottom: solid windowtext 2.25pt; border-right: solid windowtext 1.0pt; mso-border-top-alt: solid windowtext .5pt; mso-border-left-alt: solid windowtext .5pt; padding: 0in 5.4pt 0in 5.4pt; height: 1.15pt;" width="120"><span style="font-size: 9.0pt; line-height: 105%;">60-240 min </span>

<span style="font-size: 9.0pt; line-height: 105%;">(Dose dependent, after drip stopped)</span>

</td><td style="width: 184.9pt; border-top: none; border-left: none; border-bottom: solid windowtext 2.25pt; border-right: solid windowtext 1.0pt; mso-border-top-alt: solid windowtext .5pt; mso-border-bottom-alt: solid windowtext 2.25pt; mso-border-right-alt: solid windowtext .5pt; padding: 0in 5.4pt 0in 5.4pt; height: 1.15pt;" width="247">**<span style="font-size: 9.0pt; line-height: 105%;">Restricted for Use in Non-Intubated Patients.</span>**<span style="font-size: 9.0pt; line-height: 105%;"> </span>

<span style="font-size: 9.0pt; line-height: 105%;">Only approved indication is refractory agitated delirium unresponsive to other pharmacologic agents or with contraindications to other pharmacologic agents.</span>

<span style="font-size: 9.0pt; line-height: 105%;">Only available with IV access.</span>

<span style="font-size: 9.0pt; line-height: 105%;">Can cause bradycardia.</span>

<span style="font-size: 9.0pt; line-height: 105%;">Bolus dosing **not** allowed outside of OR.</span>

<span style="font-size: 9.0pt; line-height: 105%;">Restricted to ED, ICU, and OR use only.</span>

</td></tr></tbody></table>

</div></div>*\*Subject to drug availability/restrictions secondary to national drug shortage*

*<span style="font-size: 11.0pt; line-height: 105%; font-family: 'Calibri',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-font-kerning: 0pt; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;">  
</span>*

**Management Considerations for Ketamine**:

At Nebraska Medicine, ketamine is restricted to the following indications:

<span style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span>Induction for rapid sequence intubation

<span style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span>Ventilator management

<span style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span>Procedural sedation

<span style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span>Subanesthetic analgesia (restricted ordering to anesthesiology, pain management, emergency medicine, and pediatric critical care medicine)

If ketamine is required for the use of acute agitation, the institutional policy, MS\_15 for procedural sedation or MP\_33 for subanesthetic ketamine for pain management, will need to be followed.<span style="mso-spacerun: yes;"> </span>A provider must remain at bedside.

Dosing recommendations:

<span style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span>Sub-Anesthetic Ketamine for Pain

<span style="font-family: 'Courier New'; mso-fareast-font-family: 'Courier New';"><span style="mso-list: Ignore;">o<span style="font: 7.0pt 'Times New Roman';"> </span></span></span>Must be ordered by emergency medicine provider (while patient is in the ED).

<span style="font-family: 'Courier New'; mso-fareast-font-family: 'Courier New';"><span style="mso-list: Ignore;">o<span style="font: 7.0pt 'Times New Roman';"> </span></span></span>Use dosing recommendations per MP\_33

<span style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span>Procedural Sedation

<div align="center" id="bkmrk-dose-soft-max-%28singl"><table border="1" cellpadding="0" cellspacing="0" class="MsoTableGrid" style="border-collapse: collapse; border: none; mso-border-alt: solid windowtext .5pt; mso-yfti-tbllook: 1184; mso-padding-alt: 0in 5.4pt 0in 5.4pt;"><tbody><tr style="mso-yfti-irow: 0; mso-yfti-firstrow: yes;"><td style="width: 74.85pt; border: solid windowtext 1.0pt; mso-border-alt: solid windowtext .5pt; background: #E7E6E6; mso-background-themecolor: background2; padding: 0in 5.4pt 0in 5.4pt;" width="100">**<span style="font-size: 10.0pt; color: black; mso-color-alt: windowtext;">Dose</span>**

</td><td style="width: 75.35pt; border: solid windowtext 1.0pt; border-left: none; mso-border-left-alt: solid windowtext .5pt; mso-border-alt: solid windowtext .5pt; background: #E7E6E6; mso-background-themecolor: background2; padding: 0in 5.4pt 0in 5.4pt;" width="100">**<span style="font-size: 10.0pt; color: black; mso-color-alt: windowtext;">Soft Max (Single Dose)</span>**

</td><td style="width: 75.1pt; border: solid windowtext 1.0pt; border-left: none; mso-border-left-alt: solid windowtext .5pt; mso-border-alt: solid windowtext .5pt; background: #E7E6E6; mso-background-themecolor: background2; padding: 0in 5.4pt 0in 5.4pt;" width="100">**<span style="font-size: 10.0pt; color: black; mso-color-alt: windowtext;">Onset</span>**

</td><td style="width: 74.8pt; border: solid windowtext 1.0pt; border-left: none; mso-border-left-alt: solid windowtext .5pt; mso-border-alt: solid windowtext .5pt; background: #E7E6E6; mso-background-themecolor: background2; padding: 0in 5.4pt 0in 5.4pt;" width="100">**<span style="font-size: 10.0pt; color: black; mso-color-alt: windowtext;">Time to Peak</span>**

</td><td style="width: 76.05pt; border: solid windowtext 1.0pt; border-left: none; mso-border-left-alt: solid windowtext .5pt; mso-border-alt: solid windowtext .5pt; background: #E7E6E6; mso-background-themecolor: background2; padding: 0in 5.4pt 0in 5.4pt;" width="101">**<span style="font-size: 10.0pt; color: black; mso-color-alt: windowtext;">Duration</span>**

</td></tr><tr style="mso-yfti-irow: 1;"><td style="width: 74.85pt; border: solid windowtext 1.0pt; border-top: none; mso-border-top-alt: solid windowtext .5pt; mso-border-alt: solid windowtext .5pt; padding: 0in 5.4pt 0in 5.4pt;" width="100"><span style="font-size: 10.0pt;">0.5 mg/kg IV</span>

</td><td style="width: 75.35pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; mso-border-top-alt: solid windowtext .5pt; mso-border-left-alt: solid windowtext .5pt; mso-border-alt: solid windowtext .5pt; padding: 0in 5.4pt 0in 5.4pt;" width="100"><span style="font-size: 10.0pt;">1 mg/kg</span>

</td><td style="width: 75.1pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; mso-border-top-alt: solid windowtext .5pt; mso-border-left-alt: solid windowtext .5pt; mso-border-alt: solid windowtext .5pt; padding: 0in 5.4pt 0in 5.4pt;" width="100"><span style="font-size: 10.0pt;">30-60 sec</span>

</td><td style="width: 74.8pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; mso-border-top-alt: solid windowtext .5pt; mso-border-left-alt: solid windowtext .5pt; mso-border-alt: solid windowtext .5pt; padding: 0in 5.4pt 0in 5.4pt;" width="100"><span style="font-size: 10.0pt;">5-10 min</span>

</td><td style="width: 76.05pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; mso-border-top-alt: solid windowtext .5pt; mso-border-left-alt: solid windowtext .5pt; mso-border-alt: solid windowtext .5pt; padding: 0in 5.4pt 0in 5.4pt;" width="101"><span style="font-size: 10.0pt;">1-2 hours (recovery)</span>

</td></tr><tr style="mso-yfti-irow: 2; mso-yfti-lastrow: yes;"><td style="width: 74.85pt; border: solid windowtext 1.0pt; border-top: none; mso-border-top-alt: solid windowtext .5pt; mso-border-alt: solid windowtext .5pt; padding: 0in 5.4pt 0in 5.4pt;" width="100"><span style="font-size: 10.0pt;">2 mg/kg IM</span>

</td><td style="width: 75.35pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; mso-border-top-alt: solid windowtext .5pt; mso-border-left-alt: solid windowtext .5pt; mso-border-alt: solid windowtext .5pt; padding: 0in 5.4pt 0in 5.4pt;" width="100"><span style="font-size: 10.0pt;">3 mg/kg IM</span>

</td><td style="width: 75.1pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; mso-border-top-alt: solid windowtext .5pt; mso-border-left-alt: solid windowtext .5pt; mso-border-alt: solid windowtext .5pt; padding: 0in 5.4pt 0in 5.4pt;" width="100"><span style="font-size: 10.0pt;">3-4 min</span>

</td><td style="width: 74.8pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; mso-border-top-alt: solid windowtext .5pt; mso-border-left-alt: solid windowtext .5pt; mso-border-alt: solid windowtext .5pt; padding: 0in 5.4pt 0in 5.4pt;" width="100"><span style="font-size: 10.0pt;">5-30 min</span>

</td><td style="width: 76.05pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; mso-border-top-alt: solid windowtext .5pt; mso-border-left-alt: solid windowtext .5pt; mso-border-alt: solid windowtext .5pt; padding: 0in 5.4pt 0in 5.4pt;" width="101"><span style="font-size: 10.0pt;">3-4 hours (recovery)</span>

</td></tr></tbody></table>

</div>**Related Institutional Policies**:

<span style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><span style="mso-fareast-font-family: 'Times New Roman';">(MS\_15) Medical Staff: Procedural Sedation and Analgesia Administration Guidelines (Non-Anesthesiology Providers)</span>

<span style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><span style="mso-fareast-font-family: 'Times New Roman';">(TX\_01) Care of Patients: Restraint Use </span>

<span style="font-family: 'Courier New'; mso-fareast-font-family: 'Courier New';"><span style="mso-list: Ignore;">o<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><span style="mso-fareast-font-family: 'Times New Roman';">Attachment A: Alternative Interventions to Restraints</span>

<span style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><span style="mso-fareast-font-family: 'Times New Roman';">(TX\_24) Admission, Transfer and Discharge for Define Levels of Care</span>

<span style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><span style="mso-fareast-font-family: 'Times New Roman';">(MP\_33) Medication Policy and Guidelines: Low-Dose (Sub-anesthetic) Ketamine for Pain in Non-Intubated Patients</span>

**Key Contributors**:

<span style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><span style="mso-fareast-font-family: 'Times New Roman';">Krysta Baack, PharmD | Department of Pharmacy, Emergency Medicine | Principal Author</span>

<span style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><span style="mso-fareast-font-family: 'Times New Roman';">Nathan Sutera, PharmD | Department of Pharmacy, Psychiatric Emergency Services | Author</span>

<span style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><span style="mso-fareast-font-family: 'Times New Roman';">Zach Bauman, DO | Division of Acute Care Surgery, Faculty | Author</span>

**Last Updated**:

July 2024

**References:**

<span style="mso-fareast-font-family: Calibri;"><span style="mso-list: Ignore;">1.<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><span style="mso-fareast-font-family: 'Times New Roman';">Roppolo LP, Morris DW, Khan F, *et al.* Improving the management of acutely agitated patients in the emergency department through implementation of Project BETA (Best Practices in the Evaluation and Treatment of Agitation). *JACEP Open* 2020; 1:898-907.</span>

<span style="mso-fareast-font-family: Calibri;"><span style="mso-list: Ignore;">2.<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><span style="mso-fareast-font-family: 'Times New Roman';">Zareifopoulos N and Panayiotakopoulos G. Treatment options for acute agitation in psychiatric patients: theoretical and empirical evidence. *Cureus* 2019; 11(11): e6152.</span>

<span style="mso-fareast-font-family: Calibri;"><span style="mso-list: Ignore;">3.<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><span style="mso-fareast-font-family: 'Times New Roman';">Curry A, Malas N, Mroczkowski M, *et al.* </span>Updates in the assessment and management of agitation. *Focus (Am Psychiatr Publ)* 2023; 21(1): 35-45.

<span style="mso-fareast-font-family: Calibri;"><span style="mso-list: Ignore;">4.<span style="font: 7.0pt 'Times New Roman';"> </span></span></span>Lexicomp. (2024). Midazolam: dosage &amp; administration. In Lexi-Drugs Online. Retrieved \[June 27, 2024.\] from https://online.lexi.com.<span style="mso-spacerun: yes;"> </span>

<span style="mso-fareast-font-family: Calibri;"><span style="mso-list: Ignore;">5.<span style="font: 7.0pt 'Times New Roman';"> </span></span></span>Lexicomp. (2024). Olanzapine: dosage &amp; administration. In Lexi-Drugs Online. Retrieved \[June 27, 2024.\] from https://online.lexi.com.<span style="mso-spacerun: yes;"> </span>

<span style="mso-fareast-font-family: Calibri;"><span style="mso-list: Ignore;">6.<span style="font: 7.0pt 'Times New Roman';"> </span></span></span>Lexicomp. (2024). Haloperidol: dosage &amp; administration. In Lexi-Drugs Online. Retrieved \[June 27, 2024.\] from https://online.lexi.com.<span style="mso-spacerun: yes;"> </span>

<span style="mso-fareast-font-family: Calibri;"><span style="mso-list: Ignore;">7.<span style="font: 7.0pt 'Times New Roman';"> </span></span></span>Lexicomp. (2024). Dexmedetomidine: dosage &amp; administration. In Lexi-Drugs Online. Retrieved \[June 27, 2024.\] from https://online.lexi.com.<span style="mso-spacerun: yes;"> </span>

<span style="mso-fareast-font-family: Calibri;"><span style="mso-list: Ignore;">8.<span style="font: 7.0pt 'Times New Roman';"> </span></span></span>Lexicomp. (2024). Droperidol: dosage &amp; administration. In Lexi-Drugs Online. Retrieved \[June 27, 2024.\] from https://online.lexi.com.<span style="mso-spacerun: yes;"> </span>

<span style="mso-fareast-font-family: Calibri;"><span style="mso-list: Ignore;">9.<span style="font: 7.0pt 'Times New Roman';"> </span></span></span>Lexicomp. (2024). Lorazepam: dosage &amp; administration. In Lexi-Drugs Online. Retrieved \[June 27, 2024.\] from https://online.lexi.com.<span style="mso-spacerun: yes;"> </span>

<span style="mso-fareast-font-family: Calibri;"><span style="mso-list: Ignore;">10.<span style="font: 7.0pt 'Times New Roman';"> </span></span></span>Lexicomp. (2024). Ketamine: dosage &amp; administration. In Lexi-Drugs Online. Retrieved \[June 27, 2024.\] from https://online.lexi.com.<span style="mso-spacerun: yes;"> </span>

<span style="mso-fareast-font-family: Calibri;"><span style="mso-list: Ignore;">11.<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><span style="mso-fareast-font-family: 'Times New Roman';">Li M, Martinelli AN, Oliver WD, *et al*. Evaluation of ketamine for excited delirium syndrome in the adult emergency department. *J Emerg Med*. 2019; S0736-S4679(19)30802-9.</span>

<span style="mso-fareast-font-family: Calibri;"><span style="mso-list: Ignore;">12.<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><span style="mso-fareast-font-family: 'Times New Roman';">O'Brien ME, Fuh L, Raja AS, *et al*. Reduced-dose intramuscular ketamine for severe agitation in an academic emergency department. *Clin Toxicol (Phila).* 2020;58(4):294-298.</span>